complement evasion by human pathogens - lambris · surface way, the complement cascade also...

Evading the manifold attacks of the immune system is a key determinant for the survival of pathogens within their hosts. It is not surprising, therefore, that the coex-istence and co-evolution of humans and microorganisms has produced a multitude of microbial mechanisms for attenuating or escaping these attacks. As a first line of defence against pathogenic intruders, and a mediator between the innate and adaptive immune responses, the complement system is a particular focus of these evasion strategies. Although this carefully regulated cascade of enzymes, protein complexes and receptors ensures the rapid recognition and elimination of foreign struc-tures, it also offers many sites of interference that can disrupt this balanced network of protein interactions. A detailed understanding of the individual processes and the underlying interactions on a molecular level is essential for describing the mechanisms of infectious diseases and the development of new therapies. Recent discoveries of complement-targeting proteins, the avail-ability of complete microbial genome sequences and advances in experimental methods have propelled this area of research, and provide fascinating insights into complement attack and evasion. Many pathogens seem to have developed parallel routes for escaping comple-ment, and several evasion principles are shared not only among members of the same genus but even among diverse organisms, such as bacteria, viruses, fungi and parasites.

In this Review, we will provide a comprehensive over-view and update of the exciting recent developments in this field. After a short introduction that will discuss the diverse role of the complement system in defence, dis-ease and infection, the emphasis will be on the functional

and structural aspects of the evasion strategies of human pathogens. Rather than separating them by organism, we classify distinct and common mechanisms for all patho-gens based on their mode of action. In light of recent findings, the unique evasion strategies of Staphylococcus aureus will be analysed in more detail. Finally, the potential impact of these developments on prospective antimicrobial and complement-specific therapeutics will be discussed.

The human complement systemThe complement system is a central component of the innate immune response and fulfils numerous func-tions, including the recognition of foreign cells, com-munication with and activation of adaptive immunity and the removal of cellular debris (reviewed in REFS 1–5). Complement consists of a well-balanced network of circulating and cell-surface-bound proteins, which serve as substrates, enzymes or modulators of a hier-archical series of extracellular proteolytic cascades. There are three established mechanisms of comple-ment activation; these are known as the classical, lectin and alternative pathways (FIG. 1a). The initial steps that trigger these activation processes differ considerably. The classical pathway is stimulated by the recogni-tion of antigen–antibody complexes on foreign-cell surfaces by the hexameric complement component C1q. Structurally similar pattern-recognition receptors, mannose-binding lectin (MBL) and ficolins, bind to carbohydrate ligands on microbial intruders and initiate the lectin pathway. Conversely, the alternative pathway is stimulated by the spontaneous hydrolysis of native C3 or the presence of foreign surface structures

*Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA. ‡Division of Cell Biology and Biophysics, School of Biological Sciences, University of Missouri-Kansas City, 5100 Rockhill Road, Kansas City, Missouri 64110, USA. Correspondence to J.D.L. e-mail: [email protected]:10.1038/nrmicro1824

Pattern-recognition receptorA highly diverse group of soluble and surface-bound proteins that can detect specific molecular surface structures. These receptors are important for discriminating between self and non-self cells (for example, microorganisms) and are, therefore, found in various pathways of the immune system. Prominent examples in the complement system are C1q and mannose-binding lectin.

Complement evasion by human pathogensJohn D. Lambris*, Daniel Ricklin* and Brian V. Geisbrecht‡

Abstract | The human immune system has developed an elaborate network of cascades for dealing with microbial intruders. Owing to its ability to rapidly recognize and eliminate microorganisms, the complement system is an essential and efficient component of this machinery. However, many pathogenic organisms have found ways to escape the attack of complement through a range of different mechanisms. Recent discoveries in this field have provided important insights into these processes on a molecular level. These vital developments could augment our knowledge of the pathology and treatment of infectious and inflammatory diseases.

R E V I E W S

132 | FEBRUARY 2008 | VOLUME 6 www.nature.com/reviews/micro

©!2008!Nature Publishing Group!

C3aR

C3

C3a

C3bC4b

CRC5aR

C5C5a

C4C4a

C1q

Host cell

Nature Reviews | Microbiology

RCAmimicry

fI

C3b

C3aR

Cell lysis

Amplification

Opsonization

C3C3a

AP C3convertase

CP and AP C5convertases

CP and AP C5convertases

MAC

Lectinpathway

Classicalpathway

Alternative pathway

Initiation

CP C3convertase

AP C3convertase

CP C3convertase

C3b C3b iC3bC4b

CR

C5aR

AntigensCarbohydrates

Initial AP C3convertase

Initial AP C3convertase

Signalling

Antibodyinactivation

C5aRantagonism

C1 inhibition

C1-INH

RCA recruitment C3b degradation

MAC inhibition

iC3b

C3 inhibition

C5 inhibition

RCA recruitment and mimicryConvertase decay

ConvertaseinhibitionC2

inhibition

IncreasingC3b densityfB or fD

fB or fD

a Activation

b Evasion

Pathogen cell

Pathogen cell

RCA

C5b C6–C9

C2

C5C5a

C4C4a

P

P

C1qMBL or F

MBL or F

Host cellChemotaxisInflammation

Phagocytosis

Cleavage

Inhibition

Capturing

C1r/C1s(CP)

MASP (LP)

(FIG. 1a). Recent findings suggest that additional proc-esses, such as the C2-bypass6 and extrinsic protease7 pathways or properdin-mediated direct convertase assembly on microbial surfaces8, can also initiate complement activation.

All of the complement cascades culminate in the central cleavage of C3 and the generation of its active fragments C3a and C3b (FIG. 1a). Opsonization of foreign surfaces by covalently attached C3b fulfils three major functions: cell clearance by phagocytosis;

Figure 1 | Activation and evasion of complement. a | After activation of the complement system by antibody complexes (classical pathway (CP)), terminal mannose (lectin pathway (LP)) or by spontaneous and induced C3 hydrolysis (alternative pathway (AP)), the C3 convertases cleave C3 to its active fragments C3a and C3b. Covalent binding of C3b (opsonization) amplifies the cascade and mediates phagocytosis and adaptive immune responses by binding to complement receptors (CRs). Accumulation of deposited C3b also leads to the assembly of C5 convertases that activate C5 to C5a and C5b. Whereas C5b initiates the formation of the lytic membrane-attack complex (MAC), the anaphylatoxins C3a and C5a induce pro-inflammatory and chemotactic responses by binding to their receptors (C3aR and C5aR). On pathogenic surfaces, properdin (P) induces and stabilizes the AP C3 convertase, which leads to enhanced complement activity. b | Microorganisms have developed many ways to evade complement actions. Suppression of CP activation can be achieved by trapping endogenous C1 inhibitor (C1-INH) to the surface or by inactivating antibodies through the capture of their Fc regions. Whereas the recruitment of soluble regulators by capturing host proteins is a common strategy to impair downstream complement actions, certain viruses also produce structural mimics of these regulators. In addition, some microbial proteins have similar activities to CD59 in preventing MAC formation. Direct inhibition of C3, the C3 and C5 convertases, C5 or the C5a receptor (C5aR) is a prominent strategy of Staphylococcus aureus. Finally, a set of different microbial proteases can degrade many of the crucial components of the complement system. These proteases act directly or by capturing and activating a human protease. An extended list of complement evasion proteins can be found in Supplementary information S1 (table). Increased and decreased activity is represented by thick and thin arrows, respectively. F, ficolin; fB, factor B; fD, factor D; fI, factor I, MASP, MBL-associated serine protease; MBL, mannose-binding lectin; RCA, regulators of complement activation.

R E V I E W S

NATURE REVIEWS | MICROBIOLOGY VOLUME 6 | FEBRUARY 2008 | 133


AnaphylatoxinA small protein fragment (approximately 10 kDa) that is generated during the activation of complement components. C3a and C5a trigger a range of inflammatory and immune-stimulating responses by binding to their receptors (C3aR and C5aR) on various effector cells. The chemotactic activity of C5a is 100-fold higher than that of C3a; no such activities or receptors have so far been described for C4a.

Toll-like receptorA pattern-recognition receptor that recognizes a range of surface structures on pathogens (for example, proteoglycans and lipopolysaccharides). Toll-like receptors are expressed on most immune cells and their activation and signalling induces numerous inflammatory, innate and adaptive immune responses.

Short consensus repeatThe structural building block of many complement regulators and receptors (for example, factor H and CR1). These -sheet-rich domains, which are

composed of approximately 60 residues, are also found in viral complement-evasion factors and other proteins (for example, selectins, clotting factor XIII B and GABA receptors).

amplification of complement activation by the forma-tion of a surface-bound C3 convertase; and assembly of the C5 convertases. Cleavage of C5 induces the forma-tion of a multiprotein pore complex (the membrane-attack complex (MAC)), which leads to cell lysis. Both the covalent attachment of C3b and the stabilization of the C3 convertase by the complement regulator properdin are greatly encouraged by hydroxyl-rich pathogen surfaces. A series of complement receptors mediate the recognition of opsonized cells by leuko-cytes, which results in phagocytosis and the stimula-tion of the adaptive immune system (for example, by B and T cells). Finally, the anaphylatoxins C3a and C5a are released during complement activation and trigger a range of chemotactic and pro-inflammatory responses (for example, the recruitment of inflammatory cells and an increase in microvasculature permeability). In this way, the complement cascade also supports and pro-motes the function of downstream mechanisms of the immune response.

Excessive complement activation on self tissue has severe effects and can lead to the development of various diseases2,9,10. In addition to a location- and time-based restriction to immediate sites of activation, a finely tuned set of soluble and membrane-bound regulators ensure that any action of complement on host cells is either prevented or actively inhibited. These structurally similar regula-tors of complement activation (RCA) comprise comple-ment receptor 1 (CR1), factor H, factor H-like protein-1 (FHL-1), C4-binding protein (C4BP), decay-accelerating factor (DAF) and membrane cofactor protein (MCP). RCA either destabilize the C3 convertase (decay-accelera-tion activity; carried out by CR1, factor H, FHL-1, C4BP and DAF) or promote the factor-I-mediated degradation of C3b to iC3b (cofactor activity; carried out by CR1, fac-tor H, C4BP, FHL-1 and MCP). CR1 also acts as a cofactor for an additional factor-I cleavage of iC3b to C3d. A struc-turally unrelated regulator protein, CD59, prevents forma-tion of the MAC. Finally, the glycoprotein C1-inhibitor controls the activity of several enzymes that are involved in the first steps of the classical and lectin pathways (C1r, C1s and MBL-associated serine protease).

This arsenal of proteases, active components and regulators is not only essential for the efficient elimina-tion of microbial intruders, but also modulates the func-tions of the adaptive immune system11. Complement also seems to be able to communicate with other important cascades and networks in the human body. Such connec-tions have, for example, been shown for the coagulation system7. Furthermore, recent data suggest that crosstalk between complement and Toll-like receptors might have synergistic effects in the immune response to infec-tions12,13. Despite all of its benefits, however, the many proteins that are involved in this powerful network also provide pathogenic organisms with numerous locations where anti-complement strategies can be executed.

Mechanisms of complement evasionThe ability to escape the elaborate machinery of the human immune system is a key determinant in the virulence of pathogens. In fact, immune-evasion strategies are often

focused on the complement system, which is a centre-piece of innate immunity and is generally regarded as the first line of defence against pathogenic microorganisms. Our knowledge of how these escape mechanisms func-tion on a molecular level has increased remarkably in recent years. Identification of the individual pathogenic proteins and their human targets has been one crucial step in this task and the list of complement-targeting proteins is constantly growing. Despite this plethora of complement-binding proteins (Supplementary infor-mation S1 (table)), their mechanisms of action can be condensed to a few successful strategies: the recruitment or mimicking of complement regulators; the modulation or inhibition of complement proteins by direct interac-tions; and inactivation by enzymatic degradation (FIG. 1b; TABLE 1). In addition to these strategies, many microor-ganisms also possess passive evasive features — a promi-nent example is the cell wall of Gram-positive bacteria, which prevents lysis by the MAC14. The following sec-tions focus on the active complement-evasion strategies and illustrate their common and unique features.

Making use of the host’s arsenal — acquiring regulators. The presence of RCA on cell surfaces is a key deter-minant for complement function on self and non-self cells. Although most pathogens do not express RCA on their surfaces, they have found ways to adapt by stably binding the RCA that circulate in human plasma15 (FIG. 1b; TABLE 1). In fact, of all the mecha-nisms of complement evasion that are used by various pathogens, trapping RCA is by far the most widely disseminated strategy for avoiding the complement response. RCA recruitment is common in bacteria16 (for example, Escherichia coli, Borrelia burgdorferi and streptococci), but has also been described for viruses17 (for example, HIV-1), fungi18,19 (for example, Candida albicans) and parasites20 (for example, Echinococcus spp.) (Supplementary information S1 (table)). The recruitment strategy has important advantages: RCA are the natural regulators of complement and are evo-lutionarily tuned to fulfil their functions; they are pro-duced by the host and are available in relatively high concentrations; and they share common structural features, called short consensus repeat (SCR) domains, that allow the same pathogen-derived binding protein to recruit different host RCA.

Although they are less potent than the cell-surface-bound CR1, the availability of C4BP, factor H and FHL-1 as soluble proteins means that these proteins are also primary targets. All three regulators show decay acceleration and cofactor activity. Owing to their size and multivalency, the captured regulators do not usually lose their overall activity. In many cases, the recruit-ment function can be attributed to a family of similar proteins in a bacterial genus. Typical examples are the complement-regulator-acquiring proteins in Borrelia spp., porins in Neisseria spp. and the M protein family in Streptococcus spp.16 The recruitment of regulators is not restricted to soluble RCA, however. The in vivo transfer of membrane-bound regulators (MCP, DAF and CD59) between human cells has been reported21,

R E V I E W S



and the acquisition of CD59 by this mechanism has been suggested for E. coli22 and Helicobacter pylori23. Finally, some viruses camouflage themselves with RCA-containing host membrane during budding or stimulate RCA expression on the host cell24.

Certain viruses have found ways to produce soluble proteins that closely mimic the structure and function of host regulators (FIG. 1b; TABLE 1). The orthopoxvi-ruses variola (smallpox) and vaccinia express comple-ment-inhibitory proteins25,26 that consist of four SCR domains. These modules are the common building blocks and functional entities of all human RCA, and are also found in complement receptors (for example, CR2) and factors (for example, factor B). Structural analysis of the complete vaccinia virus complement-control protein (VCP)27 (FIG. 2a) clearly demonstrated its similarity to human RCA, such as DAF (FIG. 2b). Despite their small size compared with endogenous factor H (20 SCRs) and CR1 (30 SCRs), both VCP and the smallpox inhibitor of complement enzymes (SPICE) show decay acceleration as well as cofactor activity. Although these proteins vary in only 11 residues, the resulting changes in the electrostatic surface potential seem to have dra-matic effects on their regulatory potency; SPICE had a 1000-fold higher inhibitory activity for the alternative pathway than VCP28. Similar RCA-like proteins have also been described for monkeypox29 and cowpox30, two viruses that can infect humans. Interestingly, the monkeypox protein MOPICE (monkeypox inhibitor of complement proteins) contains only three SCR units and lacks decay-accelerating activity. Although a mem-brane-bound VCP homologue has been reported in

vaccinia virus (B5R)31, no complement-based functions could be detected for this protein (J.D.L., unpublished observations). Recent discoveries show that the same class of molecule is also produced in herpes viruses. A type 1 membrane protein that has four SCR repeats and dual complement-regulation activity has been isolated from Kaposi’s sarcoma-associated herpesvirus (HHV-8) and has been named Kaposica32.

The structural correspondence between these regu-lators and host RCA (FIG. 2) might reflect their ancient human origins, as the hijacking and implementation of sequences that encode beneficial host proteins has long been recognized as a hallmark of viral biology and evolution. However, viruses might not be the only microorganisms that follow this strategy. For example, complement-regulatory proteins have been described for various Ixodes spp. ticks. Both the Ixodes scapularis anti-complement protein (ISAC) and its counterpart from Ixodes ricinus (IRAC) exert decay-acceleration activity on the C3 convertases. However, any structural similari-ties between these proteins and host RCA has yet to be confirmed33,34.

Cutting through complement: pathogenic proteases. The degradation of complement components into smaller, non-functional fragments is the primary task of complement-active proteases. This class of eva-sion proteins has been reported almost exclusively in bacteria and targets a wide range of substrates. For example, the degradation of immunoglobulins (Igs) and C1q (for example, by Pseudomonas elastase (PaE) and alkaline protease (PaAP)) prevents activation

Table 1 | Examples of complement evasion proteins and their targets on host cells*

Complement evasion protein Host target

Antibody depletion

Staphylococcal protein A (SpA) IgG

Complement inhibition

Extracellular fibrinogen-binding protein (Efb) C3 and C3b-containing convertases

Staphylococcal superantigen-like protein-7 (SSL-7) C5

Staphylococcus complement inhibitor (SCIN) C3 convertases

Complement C2 receptor trispanning protein (CRIT) C2

Chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS)

C5a receptor (C5aR)

Regulators of complement activation (RCA) recruitment

Complement-regulator-acquiring protein (CRASP)

Factor H, factor H-like protein-1 (FHL-1) and C4-binding protein (C4BP)

M protein family Factor H, FHL-1 and C4BP

RCA mimicry

Variola virus complement-control protein (VCP) C3b and C3 convertases

Smallpox protein of complement enzymes (SPICE) C3b and C3 convertases

Proteolytic degradation

Staphylokinase C3b and IgG (by activation of plasmin)

Pseudomonas elastase (PaE) C3

56 kDa protease C5a*See Supplementary information S1 (table) for an extended list of microbial evasion proteins.

R E V I E W S




a

bSCR1 SCR2 SCR3 SCR4

SCR1 SCR2 SCR3 SCR4

by the classical pathway35, whereas cleavage of C5a (by the 56 kDa protease from Serratia marcescens36 or the C5a peptidases from streptococci37) efficiently disa-bles C5a-mediated pro-inflammatory and chemotactic signalling. Streptococcal pyrogenic exotoxin B was found to degrade the complement regulator proper-din, which subsequently loses its ability to stabilize the convertases on pathogenic surfaces38. Inactivation of C3 by cleavage into non-functional fragments has been described for Pseudomonas spp. proteases (PaE and PaAP) and Porphyromonas spp. proteases (PrtH)35. A rare example of non-bacterial proteases that have complement activity has been observed in the para-sitic worm Schistosoma mansoni, which degrades iC3b using a 28-kDa protease, resulting in impaired binding to CR3 (REF. 39).

The acquisition and activation of host proteases is a more recently described alternative to the enzy-matic attenuation of complement. For example, the conversion of endogenous plasminogen into plasmin on bacterial surfaces can lead to the degradation of immunoglobulin G (IgG) and C3 fragments. Although a range of bacteria express plasminogen activators and/or receptors40, this mechanism is best described for S. aureus (discussed below)41.

Direct interventions — microbial complement inhibitors. A series of highly specific protein–protein interactions is the driving force behind the sophisticated activation and regulatory mechanisms of the complement system. Any interruption of the individual binding events can break this delicate balance and destabilize comple-ment efficiency. It is surprising, therefore, that only a

few direct complement inhibitors have been identified so far; most of these have been discovered in S. aureus and their molecular mechanisms are more thoroughly discussed in the following section. The CD59-like pro-tein from B. burgdorferi is one of the few examples of a direct complement inhibitor in other bacteria. This membrane-bound protein, which has affinity for C9 and C8b, is able to inhibit MAC formation. Similarly, streptococcal inhibitor of complement (SIC) has been found to prevent MAC formation by interfering with the C5b–C7 and C5b–C8 complexes. These functions of SIC seem to be paradoxical, as streptococci are already resistant to MAC-mediated cytolysis owing to their cell-wall structure14,42. This seemingly makes SIC ineffective, or at least redundant, in this respect. Although additional non-complement function-alities have been attributed to SIC, the reason for its MAC-inhibitory potential remains unsolved.

In herpes viruses, anti-complement activities have been attributed to several glycoproteins. The most ver-satile examples are the transmembrane gC1 and gC2 from herpes simplex virus type 1 and 2, respectively. Both glycoproteins were found to bind C3b and specifi-cally accelerate the decay of the alternative pathway C3 convertase43. Although gC2 has a tenfold stronger affin-ity for C3b44, only gC1 can also inhibit the interaction of C3b with C5 and properdin45. Other glycoproteins of the herpes virus family have Fc-receptor properties and can deplete antibody recognition and the activation of the classical pathway43,46. Ig-inactivating proteins have also been identified in bacteria, such as S. aureus and group G streptococci35.

Certain human parasites also express direct com-plement inhibitors. The complement C2 receptor trispanning protein has been detected in species of Schistosoma and Trypanosoma. This protein disrupts the interaction between C2 and C4 and, therefore, prevents formation of the classical pathway C3 con-vertase47. Furthermore, the Schistosoma spp. protein paramyosin prevents MAC formation by binding C8 and C9 (REF. 48), and has other immunomodulatory activities because of its binding affinity for C1q and IgG49. Finally, soft ticks of the genus Ornithodoros express at least one protein that keeps complement activation in check during their blood meal. The 17 kDa Ornithodoros moubata complement inhibitor has been shown to directly bind to C5 and prevent its cleavage, probably by inhibiting substrate binding to the C5 convertase50,51.

Finding the right mixture of activation and inhibition. Although complement inhibition and regulation is the predominant mechanism that is used to evade host immune defence by most pathogens, there is increas-ing evidence that some microorganisms actively induce complement activity for their own purposes. One of the most intriguing examples of fine-tuning antipodal actions that is used to ‘outwit’ host immune defence is that accomplished by HIV-1 — although this virus takes advantage of opsonization to enter human cells through complement receptors (BOX 1),

Figure 2 | Molecular mimicry of human complement regulators by viruses. Certain orthopox viruses and herpes viruses express proteins that closely mimic the structure and function of human regulators of complement activation. This structural similarity is illustrated for vaccinia virus complement-control protein (VCP; Protein Data Bank (PDB) code: 1G40 (REF. 27)) (a) and human decay-accelerating factor (DAF; PDB code: 1OJV102) (b), both of which have four short consensus repeat (SCR) domains. These SCRs (or complement control protein modules) are common structural motifs in complement components (for example, complement receptors and regulators) and other proteins (such as selectins).

R E V I E W S



CR3CR2

C1q or mannose-binding lectin


RCA

Host cell

Cell entry Cell entry

EBV HIV-1

Complementactivation

Opsonization

RCA recruitment

Degradation

C3b

gp41gp120

gp350/220

iC3b

the terminal actions, such as MAC formation and phago-cytosis, must be avoided. Strikingly, the same glycopro-teins that activate complement through the classical and lectin pathways (gp41 and gp120, respectively) are also responsible for recruiting the regulators factor H and CD59 to the surface of the virus. In addition to inhibition of MAC formation by CD59, the degradation of C3b by factor I and factor H reduces amplification. However, the presence of iC3b still allows HIV-1 to hijack complement receptors to enter immune cells (BOX 1).

The diversity of the complement-targeting proteins (proteases, inhibitors and regulators) suggests that cer-tain bacteria might have developed a similarly elaborate

network of balanced complement activation and inhibi-tion. In this respect, S. aureus produces a nearly unparal-leled ensemble of immune-evasive molecules that target the complement system.

S. aureus — a master of complement evasionS. aureus is a prototypic opportunistic pathogen and a leading cause of nosocomial and community-acquired infections52. Perhaps more than any other bacterial path-ogen, S. aureus has evolved the ability to adapt to, and persist within, the diverse physiological microenviron-ments of its host (for example, skin and bones). Recent studies on this versatile bacterium have uncovered a formidable arsenal of virulence-facilitating proteins and structures that contribute to its pathogenesis.

Whereas the impact of S. aureus cell-surface-retained adhesins on host invasion and colonization has been firmly established53,54, the identities and functions of this bacterium’s immune-evading molecules have emerged only recently (reviewed in REFS 35,55–57). Several studies have revealed new mechanisms of immune evasion and modulation, and S. aureus has developed into a model system to study the fascinating interplay of host–pathogen interactions. Some strains synthe-size capsular polysaccharides58 that have been shown to impede antibody recognition59,60 and interfere with opsonization and C3b recognition by its receptors61. As the peptidoglycan-rich structure of its Gram-positive cell wall renders the bacterium resistant to MAC forma-tion42,55, most of the active evasion processes of S. aureus target the initial, amplifying and pro-inflammatory steps of complement activation.

Prevention of complement initiation. There are several mechanisms through which S. aureus impairs initiation of the classical pathway. Among these, the structure and function of staphylococcal protein A (SpA) (FIG. 3a) has been characterized most extensively. This surface-bound protein recognizes the Fc domain of Igs with high affinity62,63, which results in inverted tagging and block-age of the C1q (and Fc receptor) binding sites. It has been shown that SpA can also bind to the C1q receptor gC1qR/p33, which is highly expressed on the surface of activated platelets and endothelial cells64. However, this mechanism might be more closely associated with cell adhesion, through bridging to fibrinogen, than immune evasion65. Combined with the recent discovery that SpA can bind to von Willebrand factor and tumour-necrosis factor receptor 1 (REFS 66,67), these findings could reflect a far more versatile role for SpA than was initially real-ized. Interestingly, a second, less-characterized protein that has Ig-binding properties, called Sbi (S. aureus IgG-binding protein), has been described68. Whether Sbi shares the same physiological versatility as SpA remains to be established.

Distinct use of proteolytic enzymes. Even for pro-teases, S. aureus has developed an indirect but highly efficient way of counteracting complement. Although staphylokinase is not an enzyme itself, the forma-tion of a complex with plasminogen converts this

Box 1 | Hitchhiking with complement to enter host cells

Many human pathogens increase their virulence by avoiding confrontation with complement components or inactivating them through inhibition and degradation. However, a small group of pathogens, predominantly viruses, follow a completely different strategy by using complement receptors (CR) as an entry port into host cells. The general principle of binding to human target receptors using surface proteins, with subsequent internalization, is common to most viruses89, yet only a few target complement proteins3,17. For example, Epstein–Barr virus (EBV) expresses the glycoprotein gp350/220, which specifically interacts with CR2 on B cells and immature T cells (see the figure, left), ultimately causing infectious mononucleosis (Pfeiffer’s disease)90,91. In addition, surface-bound complement regulators serve as targets for the measles virus (haemagglutinin binds to membrane cofactor protein (MCP))92, human herpesvirus 6 (glycoprotein H binds to MCP)93 and some enteroviruses (coxsackievirus and echovirus bind to decay-accelerating factor (DAF))17. Similarly, surface-bound complement regulators, such as DAF and MCP, are recognized by other microbial proteins (for example, the Dr adhesin of Escherichia coli94) and have important roles in the infectivity and colonization of these pathogens.

Even without expressing complement-specific surface proteins, pathogens have found intriguing ways to use the hitchhiking principle — they voluntarily activate complement to become opsonized and take advantage of the deposited C3 fragments to interact with complement receptors on human cells. This formidable strategy has been observed in viruses (for example, HIV-1) (see the figure, right)3,95 and Mycobacterium tuberculosis, both of which use CR3 (REF. 96). However, the destructive potential of complement requires that the pathogen keeps complement activation in check by other mechanisms, such as the recruitment of host regulators of complement activity (RCA). Specific blockage of these activation and attachment steps could be a promising approach in the development of antimicrobial therapies.

R E V I E W S




a

b

SpA(B module)

Target: IgGsFunction: Attenuates classical

pathway

Efb(Carboxyl terminus)

SCIN

C3 (C3d domain)Inhibits C3 activation

C3 convertasesInhibits C3 activation

SSL-7 CHIPS

C5a receptorInhibits C5a signalling

Target: C5Function: Inhibits C5 activation

Human C5a

C5a receptorsReceptor activation

-defensinA cationic, cyclic, cysteine-rich peptide of 15–20 amino acids that belongs to a family of antimicrobial peptides. Whereas -defensins are mainly expressed in mammalian neutrophils, other members of this family have been described in various species within mammals, insects and plants. Although these peptides are thought to primarily disrupt microbial cell walls, they might also act as immunomodulators.

endogenous protein into the active serine protease plas-min. The broad substrate spectrum of plasmin includes C3 and human IgG. Even more strikingly, plasmin was recently shown to bind to the surface of S. aureus and remove deposited IgG, C3b and iC3b from its surface, thereby reversing the effect of opsonization41. Plasmin cleavage of IgG at its hinge region might also attenuate classical-pathway activation through C1q. In addition to plasmin activation, staphylokinase directly abolishes the bactericidal properties of -defensins, which makes it an important colonization factor69. Although the anti-opsonization activities of surface-activated plasmin have so far only been described for S. aureus, the pres-ence of plasminogen activators and receptors on various other bacteria40 suggests that this strategy could be more widely prevalent.

Suppression of complement amplification. Surprisingly, no RCA-recruiting proteins have been reported for S. aureus so far. However, recent reports have described the factor-I-mediated degradation of C3b to iC3b that is independent of factor H on the sur-face of certain S. aureus strains. The overall result of

this process is the decreased efficiency of bacterial killing by phagocytic neutrophils70,71. Although these findings are suggestive of a bacterially derived cofac-tor protein, current evidence suggests that S. aureus has evolved different pathways for counteracting the downstream actions of complement. By target-ing the central components C3 and C5, most of the opsonization, amplification and signalling steps can be efficiently suppressed. In fact, there are several unique S. aureus proteins that inhibit the conversion of native C3 to C3b. Extracellular fibrinogen-binding protein (Efb) was the first C3b-binding protein to be identified in S. aureus and was shown to inhibit opsonophagocytosis by granulocytes72. Biochemical and structural studies revealed that Efb binds to the thioester-containing C3d domain of C3 through its three-helix bundle carboxy-terminal domain (Efb-C)73,74 (FIG. 3a). Recently, an Efb-homologous protein (Ehp) from S. aureus was reported75 that shares a high level of structural similarity with Efb-C. Surprisingly, Ehp can bind two molecules of C3d and is a more potent inhibitor of C3 conversion through the alternative pathway75. Both proteins produce their effects by inducing conformational changes in C3 that render this central component unable to participate in downstream activation events74,75. A recent study indi-cates that Efb and Ehp (designated Ecb in this case76) can also bind to the C3b-containing convertases and, therefore, prevent the cleavage of both C3 (amplifica-tion) and C5 (generation of C5a)76. This convertase-centred inhibition is probably a manifestation of a conformational change in C3b that has occurred upon the binding of Efb74.

S. aureus also expresses another group of small, helical proteins that block complement activation. These staphylococcal complement inhibitors (SCINs) (FIG. 3a) seem to stabilize the C3 convertases in a non-functional state, thereby efficiently blocking all three pathways77. In contrast to Efb and Ehp, SCINs bind only to the assembled C3 convertases76–78 and not to C3 or its fragments. Both the Efb and SCIN families share a high degree of structural similarity with the IgG-binding module of SpA74,78 (FIG. 3a). However, a closer inspection of these structures reveals that the spatial arrangement of the helices is distinct. SCINs are more similar to SpA than Efb or Ehp, which may partly explain the differential binding specificities of these proteins.

Inhibition on the level of C5. In addition to the inter-ference at the stage of C3, S. aureus also produces two proteins that disrupt the downstream inflammatory responses that are carried out by C5 and its activation products. Staphylococcal superantigen-like protein-7 (SSL-7) (FIG. 3b) has recently been shown to bind native C5 with high affinity, resulting in the inhibi-tion of complement-mediated haemolysis and killing of E. coli in an in vitro setting79. SSL-7 also interacts with IgA in a C5-independent manner79. Separately, the chemotaxis inhibitory protein of S. aureus (CHIPS) (FIG. 3b) was found to impair neutrophil and

Figure 3 | Complement-targeting proteins in Staphylococcus aureus. A range of S. aureus proteins that interact with targets from the complement system have been structurally analysed. a | The immunoglobulin G (IgG)-binding module of staphylococcal protein A (SpA; Protein Data Bank (PDB) code: 1BDD63), the C3-binding domain of the extracellular fibrinogen-binding protein (Efb; PDB code: 2GOM74) and staphylococcal complement inhibitor (SCIN; PDB code: 2QFF78) share similar structural motifs, but show differential functionality. b | Both staphylococcal superantigen-like protein-7 (SSL-7; PDB code: 1V1O103) and the chemotaxis inhibitory protein of S. aureus (CHIPS; PDB code: 1XEE104) attenuate complement on the level of C5, but bind to unrelated targets (C5 protein and C5a receptor, respectively). The solution structure of human C5a (obtained by nuclear magnetic resonance at pH 5.2; PDB code: 1KJS105) is shown as a comparison. All protein-structure representations are coloured according to their secondary structure ( -helices in red and -sheets in yellow).

R E V I E W S



-grasp domainA structural fold that consists of anti-parallel -strands that ‘grasp’ a single -helix. Initially described as the central structural element of ubiquitin, this fold was later identified in several other proteins. Despite its small size, it has a wide range of functions and is present in enzymatic, binding and signalling proteins. -grasp domains are central elements in the structures of a number of bacterial immune-evasion proteins.

monocyte responses to C5a signalling, primarily by interacting with and antagonizing the C5a recep-tor80–82. Although CHIPS does not share substantial homology in either sequence or secondary structure with the natural ligand C5a (FIG. 3b), the similar overall shape and size of these molecules might explain their competition for the same receptor. Interestingly, and despite their structurally and functionally unrelated targets (native C5 and C5a receptor, respectively), the structures of SSL-7 and CHIPS share some simi-larities55 (FIG. 3b). In this respect, the prominent fold that is observed in both proteins is related to the

-grasp domains that are found in several bacterial superantigens and superantigen-like proteins82,83, and are representative of a large family of bacterial immune-evasion proteins.

Therapeutic potentialOur increasing knowledge of individual microbial agents, their human targets and their mechanisms of action could not only facilitate our understanding of microbial infection but also pave the way towards new therapeutics. Currently, our arsenal of antibiotic drugs is becoming alarmingly ineffective against many severe infectious diseases and the pipeline of novel therapeutic concepts is thin. In the past, drug-screening initiatives focused mainly on bacterial metabolism targets rather than immune evasion84. Nevertheless, recent discover-ies of complement-attenuating proteins have revealed some promising, albeit indirect, targets for therapeutic intervention. One potential limitation of this approach is that microorganisms often have multiple, sometimes redundant, evasion mechanisms15, and not all of these are equally important in pathogenesis. For example, the acquisition of factor H is not essential for the mammalian infection of B. burgdorferi85. Although confirmation of individual proteins as virulence fac-tors by in vivo mutational studies should be a first and crucial step for selecting drug targets, it is clear that classifying promising targets by basic research will provide the foundation of any such development efforts. To this end, governmental initiatives, such as that implemented by the United States Food and Drug Administration (FDA) — for example, the Antibiotic Safety and Innovation amendment to the Revitalization Act and the Orphan Drug Act — may provide new incentives for antibiotic drug development in which evasion strategies are targeted86.

Whereas the development of new antibiotics might represent a speculative endeavour, the path towards the development of new therapeutics for complement-mediated diseases seems clearer. Increased activation or insufficient regulation of this attack system on human cells is known to induce an ever-growing list of autoimmune, inflammatory and ischaemic conditions9. In many cases, the mechanisms that are involved have been revealed and numerous attractive pharmacologi-cal targets within the complement network have been identified2. Nonetheless, the number of anti-complement therapeutics on the market remains surprisingly lim-ited10. In this respect, many microbial proteins are adept

at inhibiting the complement response, and these mol-ecules provide a broad structural and functional frame-work for complement-modulating agents. Although the therapeutic administration of soluble forms of human RCA has long been considered to be an ideal method for supporting the natural regulation of complement, their size (for example, soluble CR1) or restricted activ-ity (for example, soluble DAF and MCP) has limited this approach. In this context, the development of modified, non-immunogenic viral RCA mimics based on SPICE and VCP could overcome some of these limitations, as they have high decay-acceleration and cofactor activity but are comparatively small. Indeed, VCP has been tested in an in vitro model of Alzheimer’s disease and animal models of head trauma87,88. Furthermore, the structural information on these highly potent mimics27,28 could serve as a template for designing modified host RCA that have enhanced functional properties.

The versatile arsenal of direct complement inhibitors that is provided by S. aureus could be another promis-ing source of drug templates. As potent inhibitors of the alternative pathway, proteins such as Efb, Ehp and SCIN have clinical potential for pathological conditions in which the excessive or uncontrolled generation of C3b seems to result in disease (for example, age-related macular degeneration). Owing to its broad specificity for all C3 convertases, SCIN could also be effective for conditions in which activation of the classical pathway is involved (for example, systemic lupus erythematosus). Finally, impairing the signalling function of the C5a receptor using CHIPS could serve as a new approach for a range of inflammatory disorders. Although all these proteins are highly soluble and can be expressed in high quantities, their potential immunogenicity could severely limit their direct use as therapeutics, as has recently been shown for CHIPS82. However, the avail-ability of robust structural data for these proteins (in some cases, even as co-crystals with their human target (BOX 2)) should facilitate the rational design of smaller, synthetic compounds that mimic the potent functions of these microbial proteins.

PerspectivesThe coexistence of humans and microorganisms has generated a fascinating interplay of mechanisms that maintain the balance between infection, defence and evasion. For many infectious diseases, however, this bal-ance is changed in favour of the pathogenic intruders. Alongside many other factors, such as cell adhesion and entry or colonization efficiency, avoiding the attacks of the immune system is a key determinant of microbial survival inside an often hostile host environment. The diverse and elaborate evasion strategies that are discussed here illustrate the importance of the human complement system as a target for immune escape.

The new structural insights into complement evasion, combined with our increased knowledge of complement functions in microbial defence and human disease, provide an exciting platform for long-awaited progress in research. In this context, combinations of various techniques and more systemic approaches are

R E V I E W S




Alignment with C3

Alignment with C3b

Efb-C

C3d

an important premise for coping with the complex nature of host–pathogen interactions. The continued availability of sequenced microbial genomes can only supplement our list of known complement-targeting proteins. With an eye to the future, continued studies

on such mechanisms of immune evasion and comple-ment inhibition should not only further our under-standing of these host–pathogen interactions, but also provide vital insights into better treatment strategies for many types of human diseases.

Box 2 | Building structure into complement evasion

The recent increase in structural information for microbial evasion proteins and individual complement components (reviewed in REFS 97,98) has vitally enriched our comprehension of immune-escape mechanisms. However, for a detailed understanding of the underlying processes, and the development of therapeutic interventions, knowledge of the co-crystal structures between pathogenic proteins and their complement targets would be highly beneficial. Except for the early examples of staphylococcal protein A (SpA) and streptococcal protein G (SpG), which bind to the Fc portion of immunoglobulin G (IgG)99,100, no such structural information has been available. Fortunately, the recent release of the complex structures between C3d and two staphylococcal inhibitors — the carboxyl terminus of extracellular fibrinogen-binding protein (Efb-C)74 (Protein Data Bank (PDB) code: 2GOX) and Efb-homologous protein (Ehp)75 (PDB code: 2NOJ) — have provided a first and important step in this direction. On the one hand, a detailed characterization of the binding interface between bacterial and host proteins can identify key residues and essential thermodynamic properties for the interaction. For example, electrostatic contributions have not only been found to be highly important in the case of Efb and Ehp, in which the mutation of two charged residues to alanine completely abolished C3d binding and complement inhibition74,75, but also for vaccinia virus complement control protein (VCP) and smallpox inhibitor of complement enzymes (SPICE)28. This could indicate a general principle of complement-targeted interaction that needs to be observed and validated in the future. On the other hand, the combination of structural information with biophysical and biochemical methods provides a fascinating insight into the molecular mechanism of C3 inhibition by Efb and Ehp. Whereas direct binding studies indicate preferential binding to native C3, rather than its active fragment C3b, biochemical data suggest a conformational change is induced upon complex formation. Structural alignment of the Efb-C–C3d co-crystal with the C3d domains of native C3 and C3b supported this hypothesis; whereas Efb-C might contact additional sites in C3, its docking to C3b led to steric hindrance (see the figure). This example shows how detailed structural information, combined with biochemical and interaction data101, can further propel this area of research.

1. Lambris, J. D., Sahu, A. & Wetsel, R. A. in The Human Complement System in Health and Disease (eds Volanakis, J. E. & Frank, M. M.) 83–118 (Marcel Dekker, New York, 1998).

2. Lambris, J. D. & Holers, V. M. (eds) Therapeutic Interventions in the Complement System (Humana, Totowa, 2000).

3. Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 344, 1058–1066 (2001).

4. Walport, M. J. Complement. Second of two parts. N. Engl. J. Med. 344, 1140–1144 (2001).References 3 and 4 provide a brief overview of the complement system and its ambiguous involvement in infections and other diseases.

5. Lambris, J. D. (ed.) Current Topics in Complement (Springer, New York, 2006).

6. Atkinson, J. P. & Frank, M. M. Bypassing complement: evolutionary lessons and future implications. J. Clin. Invest. 116, 1215–1218 (2006).

7. Markiewski, M. M., Nilsson, B., Nilsson Ekdahl, K., Mollnes, T. E. & Lambris, J. D. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28, 184–192 (2007).Presents the interesting connections between the complement and the coagulation systems, and discusses their impact on disease and the immune response.

8. Spitzer, D., Mitchell, L. M., Atkinson, J. P. & Hourcade, D. E. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J. Immunol. 179, 2600–2608 (2007).

9. Volanakis, J. E. & Frank, M. M. (eds) The Human Complement System in Health and Diseases (Marcel Dekker, New York, 1998).

10. Ricklin, D. & Lambris, J. D. Complement-targeted therapeutics. Nature Biotechnol. 25, 1265–1275 (2007).A current overview of the complement-specific drugs that are on the market and in clinical trials, and a discussion of how endogenous, pathogen-derived or synthetic drugs can be used to develop such therapeutics.

11. Morgan, B. P., Marchbank, K. J., Longhi, M. P., Harris, C. L. & Gallimore, A. M. Complement: central to innate immunity and bridging to adaptive responses. Immunol. Lett. 97, 171–179 (2005).

R E V I E W S



12. Hawlisch, H. et al. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22, 415–426 (2005).

13. Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110, 228–236 (2007).

14. Joiner, K., Brown, E., Hammer, C., Warren, K. & Frank, M. Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7 S. pneumoniae without causing bacterial killing. J. Immunol. 130, 845–849 (1983).

15. Zipfel, P. F., Wurzner, R. & Skerka, C. Complement evasion of pathogens: common strategies are shared by diverse organisms. Mol. Immunol. 44, 3850–3857 (2007).A supplementary description of the current topics in the field of complement evasion, with the focus on redundancy and multiplicity, the acquisition of host regulators and simultaneous binding to other host proteins.

16. Kraiczy, P. & Würzner, R. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol. Immunol. 43, 31–44 (2006).

17. Bernet, J., Mullick, J., Singh, A. K. & Sahu, A. Viral mimicry of the complement system. J. Biosci. 28, 249–264 (2003).A broad overview of the use of complement proteins by viruses that discusses immune evasion and cell attachment and entry.

18. Meri, T. et al. The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect. Immun. 72, 6633–6641 (2004).

19. Meri, T. et al. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect. Immun. 70, 5185–5192 (2002).

20. Inal, J. M. Parasite interaction with host complement: beyond attack regulation. Trends Parasitol. 20, 407–412 (2004).

21. Kooyman, D. L. et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 269, 89–92 (1995).

22. Rautemaa, R., Jarvis, G. A., Marnila, P. & Meri, S. Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59). Infect. Immun. 66, 1928–1933 (1998).

23. Rautemaa, R. et al. Survival of Helicobacter pylori from complement lysis by binding of GPI-anchored protectin (CD59). Gastroenterology 120, 470–479 (2001).

24. Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J. & Ploegh, H. L. Viral subversion of the immune system. Annu. Rev. Immunol. 18, 861–926 (2000).

25. McKenzie, R., Kotwal, G. J., Moss, B., Hammer, C. H. & Frank, M. M. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166, 1245–1250 (1992).

26. Rosengard, A. M., Liu, Y., Nie, Z. & Jimenez, R. Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc. Natl Acad. Sci. USA 99, 8808–8813 (2002).

27. Murthy, K. H. et al. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104, 301–311 (2001).

28. Sfyroera, G., Katragadda, M., Morikis, D., Isaacs, S. N. & Lambris, J. D. Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J. Immunol. 174, 2143–2151 (2005).

29. Liszewski, M. K. et al. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J. Immunol. 176, 3725–3734 (2006).

30. Miller, C. G., Shchelkunov, S. N. & Kotwal, G. J. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology 229, 126–133 (1997).

31. Engelstad, M., Howard, S. T. & Smith, G. L. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188, 801–810 (1992).

32. Mullick, J., Bernet, J., Singh, A. K., Lambris, J. D. & Sahu, A. Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) open reading frame 4 protein (kaposica) is a functional homolog of complement control proteins. J. Virol. 77, 3878–3881 (2003).

33. Daix, V. et al. Ixodes ticks belonging to the Ixodes ricinus complex encode a family of anticomplement proteins. Insect Mol. Biol. 16, 155–166 (2007).

34. Valenzuela, J. G., Charlab, R., Mather, T. N. & Ribeiro, J. M. Purification, cloning, and expression of a novel salivary anticomplement protein from the tick, Ixodes scapularis. J. Biol. Chem. 275, 18717–18723 (2000).

35. Rooijakkers, S. H. & van Strijp, J. A. Bacterial complement evasion. Mol. Immunol. 44, 23–32 (2007).

36. Oda, T. et al. Inactivation of chemotactic activity of C5a by the serratial 56-kilodalton protease. Infect. Immun. 58, 1269–1272 (1990).

37. Chmouryguina, I., Suvorov, A., Ferrieri, P. & Cleary, P. P. Conservation of the C5a peptidase genes in group A and B streptococci. Infect. Immun. 64, 2387–2390 (1996).

38. Tsao, N. et al. Streptococcal pyrogenic exotoxin B cleaves properdin and inhibits complement-mediated opsonophagocytosis. Biochem. Biophys. Res. Commun. 339, 779–784 (2006).

39. Ghendler, Y., Parizade, M., Arnon, R., McKerrow, J. H. & Fishelson, Z. Schistosoma mansoni: evidence for a 28-kDa membrane-anchored protease on schistosomula. Exp. Parasitol. 83, 73–82 (1996).

40. Lahteenmaki, K., Kuusela, P. & Korhonen, T. K. Bacterial plasminogen activators and receptors. FEMS Microbiol. Rev. 25, 531–552 (2001).

41. Rooijakkers, S. H., van Wamel, W. J., Ruyken, M., van Kessel, K. P. & van Strijp, J. A. Anti-opsonic properties of staphylokinase. Microbes Infect. 7, 476–484 (2005).

42. Frank, M. M. Annihilating host defense. Nature Med. 7, 1285–1286 (2001).

43. Lubinski, J., Nagashunmugam, T. & Friedman, H. M. Viral interference with antibody and complement. Semin. Cell Dev. Biol. 9, 329–337 (1998).

44. Rux, A. H. et al. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b. Virology 294, 324–332 (2002).

45. Kostavasili, I. et al. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J. Immunol. 158, 1763–1771 (1997).

46. Favoreel, H. W., Van de Walle, G. R., Nauwynck, H. J. & Pensaert, M. B. Virus complement evasion strategies. J. Gen. Virol. 84, 1–15 (2003).

47. Inal, J. M. & Sim, R. B. A Schistosoma protein, Sh-TOR, is a novel inhibitor of complement which binds human C2. FEBS Lett. 470, 131–134 (2000).

48. Deng, J., Gold, D., LoVerde, P. T. & Fishelson, Z. Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin. Infect. Immun. 71, 6402–6410 (2003).

49. Gobert, G. N. & McManus, D. P. Update on paramyosin in parasitic worms. Parasitol. Int. 54, 101–107 (2005).

50. Nunn, M. A. et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J. Immunol. 174, 2084–2091 (2005).

51. Roversi, P. et al. The structure of OMCI, a novel lipocalin inhibitor of the complement system. J. Mol. Biol. 369, 784–793 (2007).

52. Lowy, F. D. Staphylococcus aureus infections. N. Engl. J. Med. 339, 520–532 (1998).

53. Patti, J. M., Allen, B. L., McGavin, M. J. & Hook, M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu. Rev. Microbiol. 48, 585–617 (1994).

54. Foster, T. J. & Hook, M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6, 484–488 (1998).

55. Chavakis, T., Preissner, K. T. & Herrmann, M. The anti-inflammatory activities of Staphylococcus aureus. Trends Immunol. 28, 408–418 (2007).This comprehensive review discusses how S. aureus uses various target points (including complement) to escape the attack of the immune system.

56. Foster, T. J. Immune evasion by staphylococci. Nature Rev. Microbiol. 3, 948–958 (2005).

57. Rooijakkers, S. H., van Kessel, K. P. & van Strijp, J. A. Staphylococcal innate immune evasion. Trends Microbiol. 13, 596–601 (2005).

58. O’Riordan, K. & Lee, J. C. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 17, 218–234 (2004).

59. Peterson, P. K. et al. Dichotomy between opsonization and serum complement activation by encapsulated staphylococci. Infect. Immun. 20, 770–775 (1978).

60. Cunnion, K. M., Lee, J. C. & Frank, M. M. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect. Immun. 69, 6796–6803 (2001).

61. Verbrugh, H. A., Peterson, P. K., Nguyen, B. Y., Sisson, S. P. & Kim, Y. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. J. Immunol. 129, 1681–1687 (1982).

62. Cedergren, L., Andersson, R., Jansson, B., Uhlen, M. & Nilsson, B. Mutational analysis of the interaction between staphylococcal protein A and human IgG1. Protein Eng. 6, 441–448 (1993).

63. Gouda, H. et al. Three-dimensional solution structure of the B domain of staphylococcal protein A: comparisons of the solution and crystal structures. Biochemistry 31, 9665–9672 (1992).

64. Nguyen, T., Ghebrehiwet, B. & Peerschke, E. I. Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect. Immun. 68, 2061–2068 (2000).

65. Peerschke, E. I., Bayer, A. S., Ghebrehiwet, B. & Xiong, Y. Q. gC1qR/p33 blockade reduces Staphylococcus aureus colonization of target tissues in an animal model of infective endocarditis. Infect. Immun. 74, 4418–4423 (2006).

66. Hartleib, J. et al. Protein A is the von Willebrand factor binding protein on Staphylococcus aureus. Blood 96, 2149–2156 (2000).

67. Gómez, M. I. et al. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nature Med. 10, 842–848 (2004).

68. Zhang, L., Jacobsson, K., Vasi, J., Lindberg, M. & Frykberg, L. A second IgG-binding protein in Staphylococcus aureus. Microbiology 144, 985–991 (1998).

69. Jin, T. et al. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 172, 1169–1176 (2004).

70. Cunnion, K. M., Hair, P. S. & Buescher, E. S. Cleavage of complement C3b to iC3b on the surface of Staphylococcus aureus is mediated by serum complement factor I. Infect. Immun. 72, 2858–2863 (2004).

71. Cunnion, K. M., Buescher, E. S. & Hair, P. S. Serum complement factor I decreases Staphylococcus aureus phagocytosis. J. Lab. Clin. Med. 146, 279–286 (2005).

72. Lee, L. Y. et al. Inhibition of complement activation by a secreted Staphylococcus aureus protein. J. Infect. Dis. 190, 571–579 (2004).

73. Lee, L. Y., Liang, X., Hook, M. & Brown, E. L. Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb). J. Biol. Chem. 279, 50710–50716 (2004).

74. Hammel, M. et al. A structural basis for complement inhibition by Staphylococcus aureus. Nature Immunol. 8, 430–437 (2007).Describes the first co-crystal structure between a microbial complement-evasion protein and its host target domain; also elucidates the inhibition mechanism on a molecular level by combining biochemical and biophysical approaches.

75. Hammel, M. et al. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J. Biol. Chem. 282, 30051–30061 (2007).

76. Jongerius, I. et al. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 204, 2461–2471 (2007).

77. Rooijakkers, S. H. M. et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nature Immunol. 6, 920–927 (2005).

78. Rooijakkers, S. H. M. et al. Staphylococcal complement inhibitor: structure and active sites. J. Immunol. 179, 2989–2998 (2007).The authors describe the crystal structure of a SCIN protein and identify its functional sites by analysing protein chimeras of SCIN and an inactive homologue.

79. Langley, R. et al. The staphylococcal superantigen-like protein 7 binds IgA and complement C5 and inhibits IgA-FcaRI binding and serum killing of bacteria. J. Immunol. 174, 2926–2933 (2005).

80. de Haas, C. J. et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med. 199, 687–695 (2004).

81. Postma, B. et al. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a

R E V I E W S



and formylated peptide receptor. J. Immunol. 172, 6994–7001 (2004).

82. Wright, A. J. et al. Characterisation of receptor binding by the chemotaxis inhibitory protein of Staphylococcus aureus and the effects of the host immune response. Mol. Immunol. 44, 2507–2517 (2007).

83. Geisbrecht, B. V., Hamaoka, B. Y., Perman, B., Zemla, A. & Leahy, D. J. The crystal structures of EAP domains from Staphylococcus aureus reveal an unexpected homology to bacterial superantigens. J. Biol. Chem. 280, 17243–17250 (2005).

84. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29–40 (2007).Although not directly related to complement evasion, this insider view on new screening initiatives for antibiotic drugs by pharmaceutical companies provides noteworthy information on targets and challenges for this endeavour.

85. Woodman, M. E. et al. Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infection. Infect. Immun. 75, 3131–3139 (2007).

86. A step in the right direction. Nature Rev. Drug Discov. 6, 419 (2007).

87. Daly, J. & Kotwal, G. J. Pro-inflammatory complement activation by the A peptide of Alzheimer’s disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol. Aging 19, 619–627 (1998).

88. Pillay, N. S., Kellaway, L. A. & Kotwal, G. J. Vaccinia virus complement control protein significantly improves sensorimotor function recovery after severe head trauma. Brain Res. 1153, 158–165 (2007).

89. Marsh, M. & Helenius, A. Virus entry: open sesame. Cell 124, 729–740 (2006).

90. Nemerow, G. R., Mold, C., Schwend, V. K., Tollefson, V. & Cooper, N. R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein–Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61, 1416–1420 (1987).

91. Tsoukas, C. D. & Lambris, J. D. Expression of EBV/C3d receptors on T cells: biological significance. Immunol. Today 14, 56–59 (1993).

92. Naniche, D. et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67, 6025–6032 (1993).

93. Santoro, F. et al. Interaction of glycoprotein H of human herpesvirus 6 with the cellular receptor CD46. J. Biol. Chem. 278, 25964–25969 (2003).

94. Nowicki, B., Hart, A., Coyne, K. E., Lublin, D. M. & Nowicki, S. Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell–cell interaction. J. Exp. Med. 178, 2115–2121 (1993).

95. Datta, P. K. & Rappaport, J. HIV and complement: hijacking an immune defense. Biomed. Pharmacother. 60, 561–568 (2006).

96. Schorey, J. S., Carroll, M. C. & Brown, E. J. A macrophage invasion mechanism of pathogenic mycobacteria. Science 277, 1091–1093 (1997).

97. Janssen, B. J. & Gros, P. Structural insights into the central complement component C3. Mol. Immunol. 44, 3–10 (2007).

98. Lambris, J. D. & Morikis, D. (eds) Structural Biology of the Complement System (CRC, Boca Raton, 2005).

99. Deisenhofer, J., Jones, T. A., Huber, R., Sjodahl, J. & Sjoquist, J. Crystallization, crystal structure analysis and atomic model of the complex formed by a human Fc fragment and fragment B of protein A from Staphylococcus aureus. Hoppe-Seyler’s Z. Physiol. Chem. 359, 975–985 (1978).

100. Sauer-Eriksson, A. E., Kleywegt, G. J., Uhlen, M. & Jones, T. A. Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure 3, 265–278 (1995).

101. Ricklin, D. & Lambris, J. D. Exploring the complement interaction network using surface plasmon resonance. Adv. Exp. Med. Biol. 598, 260–278 (2007).

102. Lukacik, P. et al. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc. Natl Acad. Sci. USA 101, 1279–1284 (2004).

103. Al-Shangiti, A. M. et al. Structural relationships and cellular tropism of staphylococcal superantigen-like proteins. Infect. Immun. 72, 4261–4270 (2004).

104. Haas, P. J. et al. The structure of the C5a receptor-blocking domain of chemotaxis inhibitory protein of Staphylococcus aureus is related to a group of immune evasive molecules. J. Mol. Biol. 353, 859–872 (2005).

105. Zhang, X., Boyar, W., Toth, M. J., Wennogle, L. & Gonnella, N. C. Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy. Proteins 28, 261–267 (1997).

Acknowledgements This work was supported by National Institutes of Health grants GM-069736, GM-62134, AI-30040, AI-072106 and AI-068730, and by the research incentive funds of the School of Biological Sciences at the University of Missouri-Kansas City.

Competing interest statementThe authors declare competing financial interests: see web version for details.

DATABASESEntrez Genome: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=genomecowpox | HHV-8 | HIV-1 | monkeypox | vaccinia | variolaEntrez Genome Project: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=genomeprjBorrelia burgdorferi | Candida albicans | Escherichia coli | Helicobacter pylori | Schistosoma mansoni | Serratia marcescens | Staphylococcus aureusProtein Data Bank: http://www.rcsb.org/pdb/home/home.dohuman C5a | CHIPS | DAF | Efb | SCIN | SpA | SSL-7 | VCP

FURTHER INFORMATIONJohn D. Lambris’s homepage: http://www.lambris.net

SUPPLEMENTARY INFORMATIONSee online article: S1 (table)

ALL LINKS ARE ACTIVE IN THE ONLINE PDF

R E V I E W S



Review

Nature Reviews Microbiology 6, 132-142 (February 2008) |

doi:10.1038/nrmicro1824

Complement evasion by human pathogens

John D. Lambris1 (#a1) , Daniel Ricklin1 (#a1) & Brian V. Geisbrecht2 (#a2)

Summary

The human complement system has a pivotal role in the recognition, opsonization

and elimination of microbial intruders. This functionality is maintained by a well-

balanced interaction network of serum proteins and cell-surface receptors.

Over thousands of years of co-evolution, many microorganisms have developed

specific complement-evasion strategies to escape the attack of the immune system.

Although some of these strategies are highly specific for a single species, others are

shared more broadly among bacteria, viruses, fungi and parasites.

The most prevalent complement-evasion mechanism seems to be the capture of

soluble host complement regulators on the microbial surface or the expression of

their structural mimics. However, the inactivation of complement components by

proteolytic degradation or specific inhibition of essential functional sites is also

frequently observed.

Staphylococcus aureus has a particularly wide and diverse arsenal of complement-

evasion proteins, many of which have been discovered only recently. These

numerous evasion strategies could contribute to the high virulence of this

bacterium.

Structural biology is an indispensable tool for characterizing the structure and

function of complement-evasion proteins. Recent publications of the co-crystal

structures of evasion proteins with their human targets have allowed an even deeper

insight into the molecular basis of these escape mechanisms.

The rapid increase in the structural and functional understanding of complement

evasion could serve as an important starting point for the development of

antimicrobial or complement-targeting therapeutics.

About the authors

JOHN D. LAMBRIS

John D. Lambris is the Dr Ralph and Sallie Weaver Professor of Research Medicine at

the department of Pathology and Laboratory Medicine of the University of

Pennsylvania, Philadelphia, USA. After earning his Ph.D. in biochemistry from the

University of Patras, Greece, he dedicated his research to various aspects of the

complement system. In his laboratory at the University of Pennsylvania, he applies

ideas and methods that are embodied in engineering, computer science, physics,

chemistry and other fields to address today's challenges in complement research. His

current research efforts include the development of small-size complement inhibitors,

the crosstalk of complement with other pathways and complement evasion by

bacteria and viruses. He has been the president of the International Complement

Society and is the founder and executive director of the Aegean Conferences.

DANIEL RICKLIN

Daniel Ricklin is a postdoctoral researcher at the University of Pennsylvania,

Philadelphia, USA, in the research group of John D. Lambris. He earned his M.Sc. in

pharmaceutical sciences from the Swiss Federal Institute of Technology in Zurich,

Switzerland, and his Ph.D. in pharmaceutical chemistry from the University of Basel,

Switzerland. His current research is centred on the structure, function and interaction

network of complement proteins and the therapeutic intervention of complement-

related diseases.

BRIAN V. GEISBRECHT

Brian V. Geisbrecht is an assistant professor of cell biology and biophysics at the

University of Missouri–Kansas City (UMKC), Missouri, USA. He earned a Ph.D. in

biological chemistry from The Johns Hopkins University School of Medicine,

Maryland, USA, which was followed by a postdoctoral appointment in biophysics and

biophysical chemistry at the same institution. Since joining UMKC in 2004, his

laboratory has focused on understanding the molecular basis of host–pathogen

interactions in infectious diseases by using various complementary approaches from

structural biology (X-ray crystallography, nuclear magnetic resonance and X-ray

scattering), biophysics and biochemistry.

SU

PPLE

MEN

TAR

Y IN

FOR

MAT

ION

In

fo

rmat

pro

vid

ed b

y L

amb

ris

et

al.

(F

EB

RU

AR

Y 2

00

8)

NA

TU

RE

RE

VIE

WS

| MICRO

BIOLO

GY

www.nature.com/reviews/micro

Su

pp

lem

en

tary

in

form

ati

on

S1

(ta

ble

): M

icro

bia

l co

mp

lem

en

t-ta

rget

ing p

rote

ins

P

ath

og

en

Pro

tein

T

arg

et

Ac

tio

n

Re

f

Ba

cte

ria

Actinobacillus

sp

p.

Om

p1

00

Ou

ter

me

mb

ran

e p

rote

in 1

00

fH

Re

cru

itm

en

t o

f re

gu

lato

rs

1

Bordetella

sp

p.

FH

A

Fila

me

nto

us h

em

ag

glu

tin

in

C4

BP

, (f

H,

FH

L-1

) R

ecru

itm

en

t o

f re

gu

lato

rs

2

Borrelia

sp

p.

CR

AS

P

Co

mp

lem

en

t re

gu

lato

r-a

cq

uir

ing

su

rfa

ce

pro

tein

s

fH, F

HL

-1

Re

cru

itm

en

t o

f re

gu

lato

rs

3

Erp

O

sp

E/F

-re

late

d p

rote

ins

fH

Re

cru

itm

en

t o

f re

gu

lato

rs

4,

5

n/a

C

D5

9-lik

e p

rote

in

C8

, C

9

Pre

ve

nts

MA

C f

orm

atio

n

6

Escherichia

sp

p.

Om

pA

Ou

ter

me

mb

ran

e p

rote

in A

C

4B

P

Re

cru

itm

en

t o

f re

gu

lato

rs

7

Stc

E

Se

cre

ted

pro

tea

se

of

C1

este

rase

in

hib

ito

r C

1-I

NH

R

ecru

itm

en

t o

f C

1-I

NH

8

Tra

T

Tra

T o

ute

r m

em

bra

ne

pro

tein

C

5b

6

Pre

ve

nts

MA

C f

orm

atio

n

9

Fusobacterium

sp

p.

n/a

U

nkn

ow

n fa

cto

r fH

R

ecru

itm

en

t o

f re

gu

lato

rs

10

Haemophilus

sp

p.

n/a

U

nkn

ow

n fa

cto

r C

4B

P, fH

R

ecru

itm

en

t o

f re

gu

lato

rs

11,

12

Moraxella

sp

p.

Usp

A1

/2

Ub

iqu

ito

us s

urf

ace

pro

tein

A1

/ A

2

C4

BP

Re

cru

itm

en

t o

f re

gu

lato

rs

13

Neisseria

sp

p.

LO

S

Lip

oo

ligo

sa

cch

arid

e

fH, F

HL

-1

Re

cru

itm

en

t o

f re

gu

lato

rs

GN

A1

87

0

Ge

no

me

-de

rive

d n

eis

se

ria

l a

ntig

en

18

70

fH, F

HL

-1

Re

cru

itm

en

t o

f re

gu

lato

rs

14

Po

r O

ute

r m

em

bra

ne

po

rin

s

C4

BP

, fH

, F

HL

-1

Re

cru

itm

en

t o

f re

gu

lato

rs

15,

16

n/a

T

yp

e IV

pili

MC

P

Atta

ch

me

nt

to e

pith

elia

l ce

lls

17

Porphyromonas

sp

p.

prt

H

prt

H p

rote

ase

C3

, Ig

G

De

gra

de

s C

3 a

nd

Ig

G

18

©!2008!N

atu

re P

ub

lis

hin

g G

rou

p

SU

PPLE

MEN

TAR

Y IN

FOR

MAT

ION

In

fo

rmat

pro

vid

ed b

y L

amb

ris

et

al.

(F

EB

RU

AR

Y 2

00

8)

NA

TU

RE

RE

VIE

WS

| MICRO

BIOLO

GY


Ps

eu

do

mo

na

s s

pp

.

Pa

E

Pse

ud

om

on

as e

lasta

se

C1

q, C

3

De

gra

de

s C

1q

an

d C

3

19

Pa

AP

P

se

ud

om

on

as a

lka

line

pro

tea

se

C

1q

, C

3

De

gra

de

s C

1q

an

d C

3

19

Tu

f E

lon

ga

tio

n fa

cto

r fH

, F

HL

-1

Re

cru

itm

en

t o

f re

gu

lato

rs

20

Se

rra

tia

sp

p.

n/a

5

6 k

Da

pro

tea

se

C

5a

, C

1-I

NH

D

eg

rad

es C

5a

, d

eg

rad

es C

1-I

NH

21,

22

Sta

ph

ylo

co

cc

us

sp

p.

CH

IPS

C

he

mo

taxis

in

hib

ito

ry p

rote

in o

f S

. a

ure

us

C5

aR

A

nta

go

niz

es C

5a

23

Efb

E

xtr

ace

llula

r fib

rin

og

en

-bin

din

g p

rote

in

C3

/C3

b/C

3d

In

hib

itio

n o

f C

3 a

nd

C3

b-c

on

tain

ing

co

nve

rta

se

s

24-2

6

Eh

p a

E

fb-h

om

olo

go

us p

rote

in

C3

/C3

b/C

3d

In

hib

itio

n o

f C

3 a

nd

C3

b-c

on

tain

ing

co

nve

rta

se

s

26,

27

SA

K

Sta

ph

ylo

kin

ase

C

3b

, Ig

G

(via

Pla

sm

in)

Cle

ave

s c

om

ple

me

nt p

rote

ins,

re

mo

ve

s C

3b

fro

m s

urf

ace

28

Sb

i S

. a

ure

us Ig

G-b

ind

ing

pro

tein

Ig

G

Inh

ibits I

g in

tera

ctio

n w

ith

C1

q

29

SC

IN

Sta

ph

ylo

co

cca

l co

mp

lem

en

t in

hib

ito

r C

3 C

on

ve

rta

se

s

Inh

ibits C

3 a

ctiva

tio

n t

o C

3a

/C3

b

26,

30

Sp

A

S. a

ure

us p

rote

in A

Ig

's, g

C1

q-R

In

hib

its I

g in

tera

ctio

n w

ith

C1

q

31

SS

L-7

S

tap

hylo

co

cca

l su

pe

ran

tig

en

-lik

e p

rote

in 7

C

5

Pre

ve

nts

C5

cle

ava

ge

32

Str

ep

toc

oc

cu

s s

pp

.

Ba

c

-Pro

tein

Ig

A,

fH

Re

cru

itm

en

t o

f re

gu

lato

rs

33

Fb

a

Fib

ron

ectin

-bin

din

g p

rote

in

fH, F

HL

-1

Re

cru

itm

en

t o

f re

gu

lato

rs

34

Hic

b

Fa

cto

r H

-bin

din

g in

hib

ito

r o

f co

mp

lem

en

t fH

R

ecru

itm

en

t o

f re

gu

lato

rs

35

Ide

S

IgG

-de

gra

din

g E

nzym

e o

f S

. p

yro

ge

ne

s

IgG

C

lea

ve

s Ig

G, n

o in

tera

ctio

n w

ith

C1

q

36

M b

S

urf

ace

pro

tein

s M

fa

mily

(A

rp, S

ir,

etc

.)

fH, C

4B

P, F

HL

, F

HR

, M

CP

R

ecru

itm

en

t o

f re

gu

lato

rs

37

PL

Y

Pn

eu

mo

lysin

Ig

G, C

1q

C

om

ple

me

nt a

ctiva

tio

n /

de

ple

tio

n

38,

39

Psp

A

Pn

eu

mo

co

cca

l su

rfa

ce

pro

tein

A

un

kn

ow

n

Po

ten

tia

l im

pa

irin

g o

f A

P a

nd

co

mp

lem

en

t re

ce

pto

rs

40

Psp

C c

P

ne

um

oco

cca

l su

rfa

ce

pro

tein

C

fH

(C

3,

IgA

) R

ecru

itm

en

t o

f re

gu

lato

rs,

Po

ten

tia

l d

eg

rad

atio

n o

f C

3/C

3b

41-4

4

scp

A/B

S

tre

pto

co

cca

l C

5a

pe

ptid

ase

C

5a

D

eg

rad

es C

5a

, D

isru

pts

sig

na

ling

45-4

7

SIC

S

tre

pto

co

cca

l in

hib

ito

r o

f co

mp

lem

en

t C

5b

-7, C

5b

-8

Pre

ve

ntio

n o

f M

AC

fo

rma

tio

n

48,

49

SP

E B

S

tre

pto

co

cca

l p

yro

ge

nic

exo

toxin

B

Pro

pe

rdin

, Ig

's

De

gra

de

s P

rop

erd

in,

Ig's

36,

50

Sp

G

Str

ep

toco

ccu

s p

rote

in G

Ig

's

Inh

ibits I

g in

tera

ctio

n w

ith

C1

q

51

©!2008!N

atu

re P

ub

lis

hin

g G

rou

p

SU

PPLE

MEN

TAR

Y IN

FOR

MAT

ION

In

fo

rmat

pro

vid

ed b

y L

amb

ris

et

al.

(F

EB

RU

AR

Y 2

00

8)

NA

TU

RE

RE

VIE

WS

| MICRO

BIOLO

GY


Ye

rsin

ia s

pp

.

Ya

dA

Y

ers

inia

ad

he

sin

A

fH

Re

cru

itm

en

t o

f re

gu

lato

rs

52

Vir

us

es

He

rpe

s v

iru

se

s

gC

1/2

T

ran

sm

em

bra

ne

gly

co

pro

tein

s C

1,C

2 (

HS

V)

C3

b

Bin

ds to

C3

b,

de

ca

y a

cce

lera

tio

n (

on

ly A

P),

in

hib

its b

ind

ing

of

pro

pe

rdin

& C

5

53

gE

+g

I G

lyco

pro

tein

s E

+I

(HS

V)

IgG

F

c-r

ece

pto

r, le

ss a

ctiva

tio

n

54,

55

gp

34

,68

G

lyco

pro

tein

s 3

4, 6

8 (

HC

MV

) Ig

G

Fc-r

ece

pto

rs,

less a

ctiva

tio

n

56,

57

gp

I+g

pIV

G

lyco

pro

tein

s I+

IV (

VZ

V)

IgG

F

c-r

ece

pto

r, le

ss a

ctiva

tio

n

58

KC

P d

Ka

po

si's

sa

rko

ma

-asso

cia

ted

co

mp

lem

en

t co

ntr

ol

pro

tein

(K

SH

V)

C3

b

Mim

ics r

eg

ula

tors

(c

ofa

cto

r/d

eca

y a

cce

lera

tio

n

59

Re

tro

vir

us

es

gp

41

E

nve

lop

e g

lyco

pro

tein

41

(H

IV)

C1

q, fH

, C

D5

9

Dire

ct C

P a

ctiva

tio

n, R

ecru

itm

en

t o

f re

gu

lato

rs,

de

cre

ase

CD

59

e

xp

ressio

n

60-6

2

gp

12

0

En

ve

lop

e g

lyco

pro

tein

12

0 (

HIV

) M

BL

, fH

D

ire

ct L

P a

ctiva

tio

n,

Re

cru

itm

en

t o

f re

gu

lato

rs

62,

63

Ta

t T

ran

sa

ctiva

tor

of

tra

nscrip

tio

n (

HIV

) C

1-I

NH

In

du

ce

s C

1-I

NH

exp

ressio

n

64

Po

xv

iru

se

s

IMP

C

ow

po

x c

on

tro

l in

fla

mm

atio

n m

od

ula

tory

pro

tein

(C

ow

po

x V

iru

s)

C3

b, C

on

ve

rta

se

s

Mim

ics r

eg

ula

tors

(c

ofa

cto

r/d

eca

y a

cce

lera

tio

n)

65

MO

PIC

E

Mo

nke

yp

ox in

hib

ito

r o

f co

mp

lem

en

t e

nzym

es

(mo

nke

yp

ox v

iru

s)

C3

b

Mim

ics r

eg

ula

tors

(o

nly

co

facto

r a

ctivity)

66

SP

ICE

S

ma

llpo

x in

hib

ito

r o

f co

mp

lem

en

t e

nzym

es (

va

rio

la

viru

s)

C3

b, C

on

ve

rta

se

s

Mim

ics r

eg

ula

tors

(co

facto

r/d

eca

y a

cce

lera

tio

n)

67

VC

P

Va

ccin

ia v

iru

s c

om

ple

me

nt co

ntr

ol p

rote

in (

va

ccin

ia

viru

s)

C3

b, C

on

ve

rta

se

s

Mim

ics r

eg

ula

tors

(c

ofa

cto

r/d

eca

y a

cce

lera

tio

n)

68

Filo

vir

us

es

NS

1

No

n-s

tru

ctu

ral p

rote

in 1

(W

est

Nile

viru

s)

fH

Re

cru

itm

en

t o

f re

gu

lato

rs

69

Fu

ng

i

As

pe

rgillu

s f

um

iga

tus

n/a

U

nkn

ow

n fa

cto

r fH

, F

HL

-1, C

4B

P

RC

A r

ecru

itm

en

t 83

©!2008!N

atu

re P

ub

lis

hin

g G

rou

p

SU

PPLE

MEN

TAR

Y IN

FOR

MAT

ION

In

fo

rmat

pro

vid

ed b

y L

amb

ris

et

al.

(F

EB

RU

AR

Y 2

00

8)

NA

TU

RE

RE

VIE

WS

| MICRO

BIOLO

GY


Ca

nd

ida

alb

ica

ns

CR

AS

P-1

C

om

ple

me

nt re

gu

lato

r-a

cq

uir

ing

su

rfa

ce

pro

tein

1

fH, F

HL

-1, C

4B

P

Re

cru

itm

en

t o

f re

gu

lato

rs

84,

85

Gp

m1

p

Ph

osp

ho

gly

ce

rate

mu

tase

fH

, F

HL

-1

Re

cru

itm

en

t o

f re

gu

lato

rs

86

Pa

ras

ite

s

Ec

hin

oc

oc

cu

s s

pp

.

n/a

H

yd

atid

cyst w

all

fH

Re

cru

itm

en

t o

f re

gu

lato

rs

70

Ixo

de

s s

pp

.

IRA

C

Ixo

de

s r

icin

us a

nti-c

om

ple

me

nt p

rote

in

AP

co

nve

rta

se

D

eca

y a

cce

lera

tio

n

71

ISA

C

Ixo

de

s s

ca

pu

laris a

nti-c

om

ple

me

nt

pro

tein

A

P c

on

ve

rta

se

D

eca

y a

cce

lera

tio

n

72

On

ch

oc

erc

a s

pp

.

mf

Mic

rofila

ria

e

fH

Re

cru

itm

en

t o

f re

gu

lato

rs

73

Orn

ith

od

oro

s s

pp

.

Om

CI

Orn

ith

od

oro

s m

ou

ba

ta c

om

ple

me

nt

inh

ibito

r C

5

Bin

ds to

C5

(p

ote

ntia

lly b

locks b

ind

ing

to

C5

co

nve

rta

se

) 74

Sc

his

tos

om

a s

pp

.

CR

IT

Co

mp

lem

en

t C

2 r

ece

pto

r tr

isp

an

nin

g

C2

In

hib

its C

P c

on

ve

rta

se

fo

rma

tio

n

75

m2

8

28

kD

a m

em

bra

ne

se

rin

e p

rote

ase

iC

3b

C

lea

ve

s iC

3b

, re

str

icts

CR

3 b

ind

ing

76,

77

Pm

y e

P

ara

myo

sin

C8

, C

9,

C1

q,

IgG

P

reve

nts

MA

C f

orm

atio

n

De

cre

ase

s A

P a

ctiva

tio

n

78-8

1

Try

pa

no

so

ma

sp

p.

CR

IT

Co

mp

lem

en

t C

2 r

ece

pto

r tr

isp

an

nin

g

C2

In

hib

its C

P c

on

ve

rta

se

fo

rma

tio

n

75

T-D

AF

T

ryp

an

oso

ma

de

ca

y-a

cce

lera

tin

g fa

cto

r C

on

ve

rta

se

D

esta

bili

ze

s c

on

ve

rta

se

82

aE

hp h

as a

lso b

ee

n t

erm

ed e

xtr

acellu

lar

co

mple

ment-

bin

din

g p

rote

in (

Ecb).

bA

s H

ic is n

ot

a m

em

ber

of

the c

lassic

al P

sp

C f

am

iliy b

ut

a

Psp

C-l

ike p

rote

in,

it is lis

ted a

s s

epara

te p

rote

in.

cF

orm

er

na

mes:

cho

lin-b

indin

g p

rote

in (

Cbp

A),

Str

epto

coccus p

neu

mo

nia

e s

ecre

tory

Ig

A-

bin

din

g p

rote

in (

SpsA

) an

d p

neu

mococcal C

3-b

indin

g p

rote

in A

(P

bcA

). d

KP

C h

as a

lso b

ee

n t

erm

ed k

ap

osic

a.

e P

ara

myosin

has p

revio

usly

bee

n d

escrib

ed a

s S

chis

toso

me c

om

ple

ment

inhib

itor

pro

tein

1 (

SC

IP-1

). A

P,

altern

ative p

ath

way;

C1-I

NH

, C

1 e

ste

rase inhib

itor;

C4

BP

, C

4-

bin

din

g p

rote

in;

C5a

R,

C5

a r

ecepto

r; C

P,

cla

ssic

al path

way;

DA

F,

decay a

ccele

rating f

acto

r; f

H,

facto

r H

; F

HL,

facto

r H

-lik

e p

rote

in;

Ig,

imm

uno

glo

bulin

; M

BL,

man

nose-b

indin

g lectin;

MC

P,

me

mb

rane c

ofa

cto

r pro

tein

.

©!2008!N

atu

re P

ub

lis

hin

g G

rou

p

SU

PPLE

MEN

TAR

Y IN

FOR

MAT

ION

In

fo

rmat

pro

vid

ed b

y L

amb

ris

et

al.

(F

EB

RU

AR

Y 2

00

8)

NA

TU

RE

RE

VIE

WS

| MICRO

BIOLO

GY


Su

pp

lem

en

tary

in

form

ati

on

S1

(ta

ble

): R

efe

ren

ce

s

1.

Asa

ka

wa

, R

. e

t a

l. O

ute

r m

em

bra

ne

pro

tein

1

00

, a

ve

rsa

tile

viru

len

ce

fa

cto

r o

f A

ctin

ob

acill

us a

ctin

om

yce

tem

co

mita

ns.

Mo

l.

Mic

rob

iol. 5

0,

11

25

-11

39

(2

00

3).

2

. B

erg

ga

rd, K

., J

oh

nsso

n, E

., M

oo

i, F

.R. &

Lin

da

hl, G

. B

ord

ete

lla p

ert

ussis

bin

ds th

e

hu

ma

n c

om

ple

me

nt re

gu

lato

r C

4B

P: ro

le o

f fila

me

nto

us h

em

ag

glu

tin

in.

Infe

ct.

Im

mu

n.

65

, 3

63

8-3

64

3 (

19

97

).

3.

Kra

iczy, P

., S

ke

rka

, C

., K

irsch

fin

k, M

., B

rad

e,

V. &

Zip

fel, P

.F. Im

mu

ne

eva

sio

n o

f B

orr

elia

b

urg

do

rfe

ri b

y a

cq

uis

itio

n o

f h

um

an

co

mp

lem

en

t re

gu

lato

rs F

HL

-1/r

eco

ne

ctin

an

d

Fa

cto

r H

. E

ur.

J.

Imm

un

ol. 3

1,

16

74

-16

84

(2

00

1).

4

. H

ellw

ag

e, J.

et a

l. T

he

co

mp

lem

en

t re

gu

lato

r fa

cto

r H

bin

ds to

th

e s

urf

ace

pro

tein

Osp

E o

f B

orr

elia

bu

rgd

orf

eri.

J. B

iol. C

he

m.

27

6, 8

42

7-

84

35

(2

00

1).

5

. S

teve

nso

n, B

., E

l-H

ag

e,

N.,

Hin

es,

M.A

., M

ille

r,

J.C

. &

Ba

bb

, K

. D

iffe

ren

tia

l b

ind

ing

of h

ost

co

mp

lem

en

t in

hib

ito

r fa

cto

r H

by B

orr

elia

b

urg

do

rfe

ri E

rp s

urf

ace

pro

tein

s: a

po

ssib

le

me

ch

an

ism

un

de

rlyin

g th

e e

xp

an

siv

e h

ost

ran

ge

of L

ym

e d

ise

ase

sp

iro

ch

ete

s.

Infe

ct.

Im

mu

n.

70

, 4

91

-49

7 (

20

02

).

6.

Pa

usa

, M

. e

t a

l. S

eru

m-r

esis

tan

t str

ain

s o

f B

orr

elia

bu

rgd

orf

eri e

va

de

co

mp

lem

en

t-m

ed

iate

d k

illin

g b

y e

xp

ressin

g a

CD

59

-lik

e

co

mp

lem

en

t in

hib

ito

ry m

ole

cu

le. J.

Imm

un

ol.

17

0, 3

21

4-3

22

2 (

20

03

).

7.

Pra

sa

da

rao

, N

.V., B

lom

, A

.M.,

Vill

ou

tre

ix, B

.O.

& L

insa

ng

an

, L

.C. A

no

ve

l in

tera

ctio

n o

f o

ute

r m

em

bra

ne

pro

tein

A w

ith

C4

b b

ind

ing

pro

tein

m

ed

iate

s s

eru

m r

esis

tan

ce

of E

sch

erich

ia c

oli

K1

. J.

Imm

un

ol. 1

69

, 6

35

2-6

36

0 (

20

02

).

8.

La

the

m, W

.W., B

erg

sb

ake

n, T

. &

We

lch

, R

.A.

Po

ten

tia

tio

n o

f C

1 e

ste

rase

in

hib

ito

r b

y S

tcE

, a

m

eta

llop

rote

ase

se

cre

ted

by E

sch

erich

ia c

oli

O1

57

:H7

. T

he

Jo

urn

al o

f e

xp

erim

en

tal

me

dic

ine

19

9, 1

07

7-1

08

7 (

20

04

).

9.

Pra

mo

on

jag

o, P

. e

t a

l. R

ole

of

Tra

T p

rote

in,

an

a

ntico

mp

lem

en

tary

pro

tein

pro

du

ce

d in

E

sch

erich

ia c

oli

by R

10

0 fa

cto

r, in

se

rum

re

sis

tan

ce

. J.

Imm

un

ol. 1

48

, 8

27

-83

6 (

19

92

).

10

. F

rib

erg

, N

., C

arl

so

n, P

., M

eri

, S

. &

Ja

rva

, H

. F

uso

ba

cte

riu

m n

ecro

ph

oru

m,

the

ca

use

of

Le

mie

rre

's s

yn

dro

me

, b

ind

s fa

cto

r H

. M

ol.

Imm

un

ol. 4

4, 3

97

6 (

20

07

).

11

. H

alls

tro

m, T

., J

arv

a,

H.,

Rie

sb

eck, K

. &

Blo

m,

A.M

. In

tera

ctio

n w

ith

C4

b-b

ind

ing

pro

tein

co

ntr

ibu

tes to

no

nty

pe

ab

le H

ae

mo

ph

ilus

influ

en

za

e s

eru

m r

esis

tan

ce

. J.

Imm

un

ol. 1

78

, 6

35

9-6

36

6 (

20

07

).

12

. H

alls

tro

m, T

., Z

ipfe

l, P

.F., B

lom

, A

.M.,

F

ors

gre

n, A

. &

Rie

sb

eck, K

. H

ae

mo

ph

ilus

influ

en

za

e in

tera

cts

with

th

e h

um

an

co

mp

lem

en

t in

hib

ito

r fa

cto

r H

. M

ole

cu

lar

Imm

un

olo

gy 4

4, 3

92

6 (

20

07

).

13

. N

ord

str

om

, T

., B

lom

, A

.M.,

Fo

rsg

ren

, A

. &

R

iesb

eck, K

. T

he

em

erg

ing

pa

tho

ge

n M

ora

xe

lla

ca

tarr

ha

lis in

tera

cts

with

co

mp

lem

en

t in

hib

ito

r C

4b

bin

din

g p

rote

in th

rou

gh

ub

iqu

ito

us s

urf

ace

p

rote

ins A

1 a

nd

A2

. J.

Imm

un

ol. 1

73

, 4

59

8-

46

06

(2

00

4).

14

. M

ad

ico

, G

. e

t a

l. T

he

me

nin

go

co

cca

l va

ccin

e

ca

nd

ida

te G

NA

18

70

bin

ds th

e c

om

ple

me

nt

reg

ula

tory

pro

tein

fa

cto

r H

an

d e

nh

an

ce

s s

eru

m

resis

tan

ce

. J.

Imm

un

ol. 1

77

, 5

01

-51

0 (

20

06

).

15

. R

am

, S

. e

t a

l. B

ind

ing

of

C4

b-b

ind

ing

pro

tein

to

p

orin

: a

mo

lecu

lar

me

ch

an

ism

of se

rum

re

sis

tan

ce

of N

eis

se

ria

go

no

rrh

oe

ae

. T

he

Jo

urn

al o

f e

xp

erim

en

tal m

ed

icin

e 1

93

, 2

81

-29

5

(20

01

).

16

. R

am

, S

. e

t a

l. T

he

co

ntr

astin

g m

ech

an

ism

s o

f se

rum

re

sis

tan

ce

of

Ne

isse

ria

go

no

rrh

oe

ae

an

d

gro

up

B N

eis

se

ria

me

nin

gitid

is.

Mo

l. Im

mu

no

l.

36

, 9

15

-92

8 (

19

99

).

17

. K

alls

tro

m, H

., L

isze

wski, M

.K.,

Atk

inso

n, J.P

. &

Jo

nsso

n, A

.B. M

em

bra

ne

co

facto

r p

rote

in

(MC

P o

r C

D4

6)

is a

ce

llula

r p

ilus r

ece

pto

r fo

r p

ath

og

en

ic N

eis

se

ria

. M

ol. M

icro

bio

l. 2

5, 6

39

-6

47

(1

99

7).

1

8.

Sch

en

ke

in, H

.A.,

Fle

tch

er,

H.M

., B

od

na

r, M

. &

M

acrin

a, F

.L.

Incre

ase

d o

pso

niz

atio

n o

f a

prt

H-

de

fective

mu

tan

t o

f P

orp

hyro

mo

na

s g

ing

iva

lis

W8

3 is c

au

se

d b

y r

ed

uce

d d

eg

rad

atio

n o

f co

mp

lem

en

t-d

erive

d o

pso

nin

s. J.

Imm

un

ol.

15

4, 5

33

1-5

33

7 (

19

95

).

19

. H

on

g, Y

.Q.

& G

he

bre

hiw

et,

B.

Effe

ct

of

Pse

ud

om

on

as a

eru

gin

osa

ela

sta

se

an

d

alk

alin

e p

rote

ase

on

se

rum

co

mp

lem

en

t a

nd

is

ola

ted

co

mp

on

en

ts C

1q

an

d C

3. C

lin.

Imm

un

ol. Im

mu

no

pa

tho

l. 6

2,

13

3-1

38

(1

99

2).

2

0.

Ku

ne

rt, A

. e

t a

l. I

mm

un

e E

va

sio

n o

f th

e H

um

an

P

ath

og

en

Pse

ud

om

on

as a

eru

gin

osa

: E

lon

ga

tio

n F

acto

r T

uf

Is a

Fa

cto

r H

an

d

Pla

sm

ino

ge

n B

ind

ing

Pro

tein

. J.

Imm

un

ol. 1

79

, 2

97

9-2

98

8 (

20

07

).

21

. O

da

, T

. e

t a

l. I

na

ctiva

tio

n o

f ch

em

ota

ctic a

ctivity

of C

5a

by th

e s

err

atia

l 5

6-k

ilod

alto

n p

rote

ase

.

Infe

ct.

Im

mu

n. 5

8,

12

69

-12

72

(1

99

0).

2

2.

Mo

lla, A

., A

ka

ike

, T

. &

Ma

ed

a,

H.

Ina

ctiva

tio

n o

f va

rio

us p

rote

ina

se

in

hib

ito

rs a

nd

th

e

co

mp

lem

en

t syste

m in

hu

ma

n p

lasm

a b

y th

e

56

-kilo

da

lto

n p

rote

ina

se

fro

m S

err

atia

m

arc

esce

ns. In

fect.

Im

mu

n. 5

7,

18

68

-18

71

(1

98

9).

©!2008!N

atu

re P

ub

lis

hin

g G

rou

p

SU

PPLE

MEN

TAR

Y IN

FOR

MAT

ION

In

fo

rmat

pro

vid

ed b

y L

amb

ris

et

al.

(F

EB

RU

AR

Y 2

00

8)

NA

TU

RE

RE

VIE

WS

| MICRO

BIOLO

GY


23

. d

e H

aa

s, C

.J.

et a

l. C

he

mo

taxis

in

hib

ito

ry

pro

tein

of

Sta

ph

ylo

co

ccu

s a

ure

us, a

ba

cte

ria

l a

ntiin

fla

mm

ato

ry a

ge

nt. T

he

Jo

urn

al o

f e

xp

erim

en

tal m

ed

icin

e 1

99

, 6

87

-69

5 (

20

04

).

24

. H

am

me

l, M

. e

t a

l. A

str

uctu

ral b

asis

fo

r

co

mp

lem

en

t in

hib

itio

n b

y S

tap

hylo

co

ccu

s

au

reu

s. N

at.

Im

mu

no

l. 8

, 4

30

-43

7 (

20

07

).

25

. L

ee

, L

.Y.

et a

l. I

nh

ibitio

n o

f co

mp

lem

en

t a

ctiva

tio

n b

y a

se

cre

ted

Sta

ph

ylo

co

ccu

s a

ure

us

pro

tein

. J. In

fect.

Dis

. 1

90

, 5

71

-57

9 (

20

04

).

26

. Jo

ng

eriu

s, I.

et a

l. S

tap

hylo

co

cca

l co

mp

lem

en

t e

va

sio

n b

y v

ario

us c

on

ve

rta

se

-blo

ckin

g

mo

lecu

les. T

he

Jo

urn

al o

f e

xp

erim

en

tal

me

dic

ine

20

4, 2

46

1-2

47

1 (

20

07

).

27

. H

am

me

l, M

. e

t a

l. C

ha

racte

riza

tio

n o

f E

hp

: A

se

cre

ted

co

mp

lem

en

t in

hib

ito

ry p

rote

in f

rom

S

tap

hylo

co

ccu

s a

ure

us. J. B

iol. C

he

m.

(20

07

).

28

. R

oo

ijakke

rs, S

.H., v

an

Wa

me

l, W

.J.,

Ru

yke

n,

M.,

va

n K

esse

l, K

.P. &

va

n S

trijp

, J.A

. A

nti-

op

so

nic

pro

pe

rtie

s o

f sta

ph

ylo

kin

ase

. M

icro

be

s

Infe

ct.

7, 4

76

-48

4 (

20

05

).

29

. Z

ha

ng

, L

., J

aco

bsso

n, K

., V

asi, J

., L

ind

be

rg, M

. &

Fry

kb

erg

, L

. A

se

co

nd

Ig

G-b

ind

ing

pro

tein

in

S

tap

hylo

co

ccu

s a

ure

us. M

icro

bio

log

y 1

44

( P

t 4

), 9

85

-99

1 (

19

98

).

30

. R

oo

ijakke

rs, S

.H. e

t a

l. Im

mu

ne

eva

sio

n b

y a

sta

ph

ylo

co

cca

l co

mp

lem

en

t in

hib

ito

r th

at

acts

o

n C

3 c

on

ve

rta

se

s. N

at.

Im

mu

no

l. 6

, 9

20

-92

7

(20

05

).

31

. K

ron

va

ll, G

. &

Ge

wu

rz,

H.

Activa

tio

n a

nd

in

hib

itio

n o

f Ig

G m

ed

iate

d c

om

ple

me

nt

fixa

tio

n

by s

tap

hylo

co

cca

l p

rote

in A

. C

lin.

Exp

. Im

mu

no

l. 7

, 2

11

-22

0 (

19

70

).

32

. L

an

gle

y, R

. e

t a

l. T

he

sta

ph

ylo

co

cca

l su

pe

ran

tig

en

-lik

e p

rote

in 7

bin

ds I

gA

an

d

co

mp

lem

en

t C

5 a

nd

in

hib

its I

gA

-Fc a

lph

a R

I b

ind

ing

an

d s

eru

m k

illin

g o

f b

acte

ria

. J.

Imm

un

ol. 1

74

, 2

92

6-2

93

3 (

20

05

).

33

. A

resch

ou

g, T

., S

talh

am

ma

r-C

arl

em

alm

, M

.,

Ka

rlsso

n, I.

& L

ind

ah

l, G

. S

tre

pto

co

cca

l b

eta

pro

tein

ha

s s

ep

ara

te b

ind

ing

site

s f

or

hu

ma

n

facto

r H

an

d Ig

A-F

c.

J. B

iol. C

he

m.

27

7, 1

26

42

-1

26

48

(2

00

2).

3

4.

Pa

nd

irip

ally

, V

., W

ei, L

., S

ke

rka

, C

., Z

ipfe

l, P

.F.

& C

ue

, D

. R

ecru

itm

en

t o

f co

mp

lem

en

t fa

cto

r H

-

like

pro

tein

1 p

rom

ote

s in

tra

ce

llula

r in

va

sio

n b

y

gro

up

A s

tre

pto

co

cci. In

fect.

Im

mu

n.

71

, 7

11

9-

71

28

(2

00

3).

3

5.

Ja

nu

lczyk, R

., Ia

nn

elli

, F

., S

joh

olm

, A

.G.,

Po

zzi,

G. &

Bjo

rck, L

. H

ic, a

no

ve

l su

rfa

ce

pro

tein

of

Str

ep

toco

ccu

s p

ne

um

on

iae

th

at in

terf

ere

s w

ith

co

mp

lem

en

t fu

nctio

n.

J. B

iol. C

he

m.

27

5,

37

25

7-3

72

63

(2

00

0).

36

. vo

n P

aw

el-R

am

min

ge

n,

U. &

Bjo

rck,

L.

Ide

S

an

d S

pe

B: im

mu

no

glo

bu

lin-d

eg

rad

ing

cyste

ine

p

rote

ina

se

s o

f S

tre

pto

co

ccu

s p

yo

ge

ne

s. C

urr

. O

pin

. M

icro

bio

l. 6

, 5

0-5

5 (

20

03

).

37

. Ja

rva

, H

., J

okira

nta

, T

.S., W

urz

ne

r, R

. &

Me

ri,

S. C

om

ple

me

nt

resis

tan

ce

me

ch

an

ism

s o

f str

ep

toco

cci. M

ol. I

mm

un

ol. 4

0,

95

-10

7 (

20

03

).

38

. M

itch

ell,

T.J

., A

nd

rew

, P

.W.,

Sa

un

de

rs,

F.K

.,

Sm

ith

, A

.N. &

Bo

uln

ois

, G

.J. C

om

ple

me

nt

activa

tio

n a

nd

an

tib

od

y b

ind

ing

by p

ne

um

oly

sin

via

a r

eg

ion

of th

e to

xin

ho

mo

log

ou

s to

a

hu

ma

n a

cu

te-p

ha

se

pro

tein

. M

ol. M

icro

bio

l. 5

, 1

88

3-1

88

8 (

19

91

).

39

. P

ato

n, J.C

., R

ow

an

-Ke

lly,

B. &

Fe

rra

nte

, A

. A

ctiva

tio

n o

f h

um

an

co

mp

lem

en

t b

y t

he

p

ne

um

oco

cca

l to

xin

pn

eu

mo

lysin

. In

fect.

Imm

un

. 4

3, 1

08

5-1

08

7 (

19

84

).

40

. R

en

, B

. e

t a

l. T

he

vir

ule

nce

fu

nctio

n o

f S

tre

pto

co

ccu

s p

ne

um

on

iae

su

rfa

ce

pro

tein

A

invo

lve

s in

hib

itio

n o

f co

mp

lem

en

t a

ctiva

tio

n a

nd

im

pa

irm

en

t o

f co

mp

lem

en

t re

ce

pto

r-m

ed

iate

d

pro

tectio

n. J. Im

mu

no

l. 1

73

, 7

50

6-7

51

2 (

20

04

).

41

. D

ave

, S

., B

roo

ks-W

alte

r, A

., P

an

gb

urn

, M

.K. &

M

cD

an

iel, L

.S. P

sp

C,

a p

ne

um

oco

cca

l su

rfa

ce

p

rote

in, b

ind

s h

um

an

fa

cto

r H

. In

fect.

Im

mu

n.

69

, 3

43

5-3

43

7 (

20

01

).

42

. K

err

, A

.R. e

t a

l. T

he

co

ntr

ibu

tio

n o

f P

sp

C to

p

ne

um

oco

cca

l viru

len

ce

va

rie

s b

etw

ee

n s

tra

ins

an

d is a

cco

mp

lish

ed

by b

oth

co

mp

lem

en

t e

va

sio

n a

nd

co

mp

lem

en

t-in

de

pe

nd

en

t m

ech

an

ism

s. In

fect.

Im

mu

n. 7

4, 5

31

9-5

32

4

(20

06

).

43

. A

ng

el, C

.S., R

uze

k, M

. &

Ho

ste

tte

r, M

.K.

De

gra

da

tio

n o

f C

3 b

y S

tre

pto

co

ccu

s

pn

eu

mo

nia

e. J. In

fect. D

is. 1

70

, 6

00

-60

8

(19

94

).

44

. C

he

ng

, Q

., F

inke

l, D

. &

Ho

ste

tte

r, M

.K. N

ove

l p

urifica

tio

n s

ch

em

e a

nd

fu

nctio

ns fo

r a

C3

-b

ind

ing

pro

tein

fro

m S

tre

pto

co

ccu

s

pn

eu

mo

nia

e. B

ioch

em

istr

y 3

9,

54

50

-54

57

(2

00

0).

4

5.

Ch

mo

ury

gu

ina

, I.

, S

uvo

rov,

A.,

Fe

rrie

ri,

P. &

C

lea

ry, P

.P.

Co

nse

rva

tio

n o

f th

e C

5a

pe

ptid

ase

g

en

es in

gro

up

A a

nd

B s

tre

pto

co

cci. I

nfe

ct.

Im

mu

n.

64

, 2

38

7-2

39

0 (

19

96

).

46

. W

exle

r, D

.E.,

Ch

en

ow

eth

, D

.E. &

Cle

ary

, P

.P.

Me

ch

an

ism

of a

ctio

n o

f th

e g

rou

p A

str

ep

toco

cca

l C

5a

in

activa

tor.

Pro

c. N

atl.

Aca

d.

Sci. U

.S.A

. 8

2, 8

14

4-8

14

8 (

19

85

).

47

. W

exle

r, D

.E.,

Ne

lso

n, R

.D. &

Cle

ary

, P

.P.

Hu

ma

n n

eu

tro

ph

il ch

em

ota

ctic r

esp

on

se

to

g

rou

p A

str

ep

toco

cci: b

acte

ria

-me

dia

ted

in

terf

ere

nce

with

co

mp

lem

en

t-d

eri

ve

d

ch

em

ota

ctic fa

cto

rs.

Infe

ct. I

mm

un

. 3

9, 2

39

-24

6

(19

83

).

48

. A

ke

sso

n, P

., S

joh

olm

, A

.G.

& B

jorc

k, L

. P

rote

in

SIC

, a

no

ve

l e

xtr

ace

llula

r p

rote

in o

f S

tre

pto

co

ccu

s p

yo

ge

ne

s in

terf

erin

g w

ith

co

mp

lem

en

t fu

nctio

n.

J. B

iol. C

he

m.

27

1, 1

08

1-

10

88

(1

99

6).

4

9.

Fe

rnie

-Kin

g,

B.A

. e

t a

l. S

tre

pto

co

cca

l in

hib

ito

r o

f co

mp

lem

en

t (S

IC)

inh

ibits t

he

me

mb

ran

e

atta

ck c

om

ple

x b

y p

reve

ntin

g u

pta

ke

of

C5

67

o

nto

ce

ll m

em

bra

ne

s. Im

mu

no

log

y 1

03

, 3

90

-

39

8 (

20

01

).

©!2008!N

atu

re P

ub

lis

hin

g G

rou

p

SU

PPLE

MEN

TAR

Y IN

FOR

MAT

ION

In

fo

rmat

pro

vid

ed b

y L

amb

ris

et

al.

(F

EB

RU

AR

Y 2

00

8)

NA

TU

RE

RE

VIE

WS

| MICRO

BIOLO

GY


50

. T

sa

o, N

. e

t a

l. S

tre

pto

co

cca

l p

yro

ge

nic

exo

toxin

B

cle

ave

s p

rop

erd

in a

nd

in

hib

its c

om

ple

me

nt-

me

dia

ted

op

so

no

ph

ag

ocyto

sis

. B

ioch

em

. B

iop

hys. R

es. C

om

mu

n. 339

, 7

79

-78

4 (

20

06

).

51

. B

jorc

k, L

. &

Kro

nva

ll, G

. P

uri

fica

tio

n a

nd

so

me

pro

pe

rtie

s o

f str

ep

toco

cca

l p

rote

in G

, a

no

ve

l Ig

G-b

ind

ing

re

ag

en

t. J

. Im

mu

no

l. 133

, 9

69

-97

4

(19

84

).

52

. C

hin

a, B

., S

ory

, M

.P.,

N'G

uye

n, B

.T.,

De

B

ruye

re, M

. &

Co

rne

lis, G

.R.

Ro

le o

f th

e Y

ad

A

pro

tein

in

pre

ve

ntio

n o

f o

pso

niz

atio

n o

f Y

ers

inia

e

nte

roco

litic

a b

y C

3b

mo

lecu

les.

Infe

ct.

Im

mu

n.

61

, 3

12

9-3

13

6 (

19

93

).

53

. K

osta

va

sili

, I.

et a

l. M

ech

an

ism

of

co

mp

lem

en

t in

activa

tio

n b

y g

lyco

pro

tein

C o

f h

erp

es s

imp

lex

viru

s. J.

Imm

un

ol. 158

, 1

76

3-1

77

1 (

19

97

).

54

. Jo

hn

so

n, D

.C. &

Fe

en

str

a, V

. Id

en

tifica

tio

n o

f a

n

ove

l h

erp

es s

imp

lex v

iru

s t

yp

e 1

-in

du

ce

d

gly

co

pro

tein

wh

ich

co

mp

lexe

s w

ith

gE

an

d

bin

ds im

mu

no

glo

bu

lin.

J. V

iro

l. 61

, 2

20

8-2

21

6

(19

87

).

55

. P

ara

, M

.F.,

Ba

ucke

, R

.B. &

Sp

ea

r, P

.G.

Gly

co

pro

tein

gE

of

he

rpe

s s

imp

lex v

iru

s t

yp

e 1

: e

ffe

cts

of

an

ti-g

E o

n v

irio

n in

fectivity a

nd

on

viru

s-in

du

ce

d fc-b

ind

ing

re

ce

pto

rs.

J. V

iro

l. 41

, 1

29

-13

6 (

19

82

).

56

. A

tala

y, R

. e

t a

l. Id

en

tifica

tio

n a

nd

exp

ressio

n o

f h

um

an

cyto

me

ga

loviru

s tra

nscrip

tio

n u

nits

co

din

g fo

r tw

o d

istin

ct F

cg

am

ma

re

ce

pto

r

ho

mo

log

s. J. V

iro

l. 76

, 8

59

6-8

60

8 (

20

02

).

57

. L

ille

y, B

.N.,

Plo

eg

h,

H.L

. &

Tir

ab

assi, R

.S.

Hu

ma

n c

yto

me

ga

loviru

s o

pe

n r

ea

din

g f

ram

e

TR

L1

1/IR

L1

1 e

nco

de

s a

n im

mu

no

glo

bu

lin G

F

c-b

ind

ing

pro

tein

. J.

Viro

l. 75

, 1

12

18

-11

22

1

(20

01

).

58

. L

itw

in,

V.,

Ja

ckso

n, W

. &

Gro

se

, C

. R

ece

pto

r p

rop

ert

ies o

f tw

o v

arice

lla-z

oste

r vir

us

gly

co

pro

tein

s, g

pI a

nd

gp

IV, h

om

olo

go

us to

he

rpe

s s

imp

lex v

iru

s g

E a

nd

gI.

J. V

iro

l. 66

, 3

64

3-3

65

1 (

19

92

).

59

. S

pill

er,

O.B

. e

t a

l. C

om

ple

me

nt

reg

ula

tio

n b

y

Ka

po

si's

sa

rco

ma

-asso

cia

ted

he

rpe

sviru

s

OR

F4

pro

tein

. J. V

iro

l. 77

, 5

92

-59

9 (

20

03

).

60

. C

ho

ng

, Y

.H.

& L

ee

, M

.J.

Exp

ressio

n o

f co

mp

lem

en

t in

hib

ito

r p

rote

in C

D5

9 in

hu

ma

n

ne

uro

na

l a

nd

glia

l ce

ll lin

es t

rea

ted

with

HIV

-1

gp

41

pe

ptid

es. J. N

eu

rovir

ol. 6

, 5

1-6

0 (

20

00

).

61

. E

be

nb

ich

ler,

C.F

. e

t a

l. H

um

an

im

mu

no

de

ficie

ncy v

iru

s t

yp

e 1

activa

tes t

he

cla

ssic

al p

ath

wa

y o

f co

mp

lem

en

t b

y d

ire

ct

C1

b

ind

ing

th

rou

gh

sp

ecific

site

s in

th

e

tra

nsm

em

bra

ne

gly

co

pro

tein

gp

41

. T

he

Jo

urn

al

of e

xp

erim

en

tal m

ed

icin

e 174

, 1

41

7-1

42

4

(19

91

).

62

. S

toib

er,

H.,

Sch

ne

ide

r, R

., J

an

ato

va

, J.

&

Die

rich

, M

.P. H

um

an

co

mp

lem

en

t p

rote

ins C

3b

, C

4b

, fa

cto

r H

an

d p

rop

erd

in r

ea

ct w

ith

sp

ecific

site

s in

gp

12

0 a

nd

gp

41

, th

e e

nve

lop

e p

rote

ins

of H

IV-1

. Im

mu

no

bio

log

y 193

, 9

8-1

13

(1

99

5).

6

3.

Th

iele

ns, N

.M.,

Ta

cn

et-

De

lorm

e, P

. &

Arla

ud

, G

.J.

Inte

ractio

n o

f C

1q

an

d m

an

na

n-b

ind

ing

lectin

with

vir

use

s. Im

mu

no

bio

log

y 205

, 5

63

-5

74

(2

00

2).

6

4.

Izm

ailo

va

, E

. e

t a

l. H

IV-1

Ta

t re

pro

gra

ms

imm

atu

re d

en

dritic c

ells

to

exp

ress

ch

em

oa

ttra

cta

nts

fo

r a

ctiva

ted

T c

ells

an

d

ma

cro

ph

ag

es. N

at. M

ed

. 9

, 1

91

-19

7 (

20

03

).

65

. M

ille

r, C

.G.,

Sh

ch

elk

un

ov, S

.N. &

Ko

twa

l, G

.J.

Th

e c

ow

po

x v

iru

s-e

nco

de

d h

om

olo

g o

f th

e

va

ccin

ia v

iru

s c

om

ple

me

nt co

ntr

ol p

rote

in is a

n

infla

mm

atio

n m

od

ula

tory

pro

tein

. V

iro

log

y 229

, 1

26

-13

3 (

19

97

).

66

. L

isze

wski, M

.K.

et a

l. S

tru

ctu

re a

nd

re

gu

lato

ry

pro

file

of

the

mo

nke

yp

ox in

hib

ito

r o

f co

mp

lem

en

t: c

om

pa

riso

n t

o h

om

olo

gs in

va

ccin

ia a

nd

va

rio

la a

nd

evid

en

ce

fo

r d

ime

r fo

rma

tio

n. J.

Imm

un

ol. 176

, 3

72

5-3

73

4 (

20

06

).

67

. R

ose

ng

ard

, A

.M.,

Liu

, Y

., N

ie, Z

. &

Jim

en

ez, R

.

Va

rio

la v

iru

s im

mu

ne

eva

sio

n d

esig

n:

exp

ressio

n o

f a

hig

hly

eff

icie

nt

inh

ibito

r o

f

hu

ma

n c

om

ple

me

nt. P

roc. N

atl.

Aca

d. S

ci.

U.S

.A. 99

, 8

80

8-8

81

3 (

20

02

).

68

. M

cK

en

zie

, R

., K

otw

al, G

.J.,

Mo

ss, B

., H

am

me

r,

C.H

. &

Fra

nk,

M.M

. R

eg

ula

tio

n o

f co

mp

lem

en

t a

ctivity b

y v

accin

ia v

iru

s c

om

ple

me

nt-

co

ntr

ol

pro

tein

. J. In

fect.

Dis

. 166

, 1

24

5-1

25

0 (

19

92

).

69

. C

hu

ng

, K

.M.

et

al. W

est N

ile v

iru

s n

on

str

uctu

ral

pro

tein

NS

1 in

hib

its c

om

ple

me

nt a

ctiva

tio

n b

y

bin

din

g th

e r

eg

ula

tory

pro

tein

fa

cto

r H

. P

roc.

Na

tl.

Aca

d. S

ci. U

.S.A

. 103

, 1

91

11

-19

11

6

(20

06

).

70

. D

iaz, A

., F

err

eira

, A

. &

Sim

, R

.B. C

om

ple

me

nt

eva

sio

n b

y E

ch

ino

co

ccu

s g

ran

ulo

su

s:

se

qu

estr

atio

n o

f h

ost

facto

r H

in

th

e h

yd

atid

cyst w

all.

J.

Imm

un

ol. 158

, 3

77

9-3

78

6 (

19

97

).

71

. D

aix

, V

. e

t a

l. I

xo

de

s tic

ks b

elo

ng

ing

to

th

e

Ixo

de

s r

icin

us c

om

ple

x e

nco

de

a fa

mily

of

an

tico

mp

lem

en

t p

rote

ins.

Inse

ct. M

ol. B

iol. 16

, 1

55

-16

6 (

20

07

).

72

. V

ale

nzu

ela

, J.G

., C

ha

rla

b, R

., M

ath

er,

T.N

. &

R

ibe

iro

, J.M

. P

uri

fica

tio

n, clo

nin

g,

an

d

exp

ressio

n o

f a

no

ve

l sa

liva

ry a

ntico

mp

lem

en

t p

rote

in f

rom

th

e t

ick,

Ixo

de

s s

ca

pu

laris. J. B

iol.

Ch

em

. 275

, 1

87

17

-18

72

3 (

20

00

).

73

. M

eri,

T. e

t a

l. O

nch

oce

rca

vo

lvu

lus m

icro

fila

ria

e

avo

id c

om

ple

me

nt a

tta

ck b

y d

ire

ct b

ind

ing

of

facto

r H

. J.

Infe

ct.

Dis

. 185

, 1

78

6-1

79

3 (

20

02

).

74

. N

un

n, M

.A. e

t a

l. C

om

ple

me

nt

inh

ibito

r o

f C

5

activa

tio

n f

rom

th

e s

oft

tic

k O

rnith

od

oro

s

mo

ub

ata

. J.

Imm

un

ol. 174

, 2

08

4-2

09

1 (

20

05

).

75

. In

al, J

.M.

& S

im, R

.B.

A S

ch

isto

so

ma

pro

tein

, S

h-T

OR

, is

a n

ove

l in

hib

ito

r o

f co

mp

lem

en

t w

hic

h b

ind

s h

um

an

C2

. F

EB

S L

ett. 470

, 1

31

-1

34

(2

00

0).

7

6.

Gh

en

dle

r, Y

., P

ariza

de

, M

., A

rno

n,

R.,

M

cK

err

ow

, J.H

. &

Fis

he

lso

n, Z

. S

ch

isto

so

ma

m

an

so

ni: e

vid

en

ce

fo

r a

28

-kD

a m

em

bra

ne

-a

nch

ore

d p

rote

ase

on

sch

isto

so

mu

la. E

xp

.

Pa

rasito

l. 83

, 7

3-8

2 (

19

96

).

©!2008!N

atu

re P

ub

lis

hin

g G

rou

p

SU

PPLE

MEN

TAR

Y IN

FOR

MAT

ION

In

fo

rmat

pro

vid

ed b

y L

amb

ris

et

al.

(F

EB

RU

AR

Y 2

00

8)

NA

TU

RE

RE

VIE

WS

| MICRO

BIOLO

GY


77

. M

ariko

vsky, M

., A

rno

n,

R.

& F

ish

els

on

, Z

. S

ch

isto

so

ma

ma

nso

ni: lo

ca

liza

tio

n o

f th

e 2

8

kD

a s

ecre

ted

pro

tea

se

in

ce

rca

ria

. P

ara

site

Imm

un

ol. 12

, 3

89

-40

1 (

19

90

).

78

. D

en

g, J., G

old

, D

., L

oV

erd

e, P

.T.

& F

ish

els

on

,

Z. In

hib

itio

n o

f th

e c

om

ple

me

nt m

em

bra

ne

a

tta

ck c

om

ple

x b

y S

ch

isto

so

ma

ma

nso

ni

pa

ram

yo

sin

. In

fect.

Im

mu

n. 71

, 6

40

2-6

41

0

(20

03

).

79

. L

acle

tte

, J.P

. e

t a

l. P

ara

myo

sin

in

hib

its

co

mp

lem

en

t C

1. J. Im

mu

no

l. 148

, 1

24

-12

8

(19

92

).

80

. M

cIn

tosh

, R

.S.,

Jo

ne

s, F

.M., D

un

ne

, D

.W.,

McK

err

ow

, J.H

. &

Ple

ass,

R.J

. C

ha

racte

riza

tio

n

of im

mu

no

glo

bu

lin b

ind

ing

by s

ch

isto

so

me

s.

Pa

rasite

Im

mu

no

l. 28

, 4

07

-41

9 (

20

06

).

81

. P

ariza

de

, M

., A

rno

n, R

., L

ach

ma

nn

, P

.J. &

F

ish

els

on

, Z

. F

un

ctio

na

l a

nd

an

tig

en

ic

sim

ilari

tie

s b

etw

ee

n a

94

-kD

pro

tein

of

Sch

isto

so

ma

ma

nso

ni (S

CIP

-1)

an

d h

um

an

C

D5

9. T

he

Jo

urn

al o

f e

xp

erim

en

tal m

ed

icin

e

179

, 1

62

5-1

63

6 (

19

94

).

82

. T

am

bo

urg

i, D

.V. e

t a

l. A

pa

rtia

l cD

NA

clo

ne

of

tryp

om

astig

ote

de

ca

y-a

cce

lera

tin

g fa

cto

r (T

-D

AF

), a

de

ve

lop

me

nta

lly r

eg

ula

ted

co

mp

lem

en

t in

hib

ito

r o

f T

ryp

an

oso

ma

cru

zi, h

as g

en

etic a

nd

fu

nctio

na

l sim

ilari

tie

s t

o th

e h

um

an

co

mp

lem

en

t

inh

ibito

r D

AF

. In

fect.

Im

mu

n. 61

, 3

65

6-3

66

3

(19

93

).

83

. V

og

l, G

. e

t a

l. Im

mu

ne

eva

sio

n b

y a

cq

uis

itio

n o

f co

mp

lem

en

t in

hib

ito

rs:

Th

e m

ou

ld A

sp

erg

illu

s

bin

ds b

oth

fa

cto

r H

an

d C

4b

bin

din

g p

rote

in.

Mo

l. I

mm

un

ol. (

20

07

).

84

. M

eri,

T. e

t a

l. T

he

ye

ast C

an

did

a a

lbic

an

s b

ind

s

co

mp

lem

en

t re

gu

lato

rs fa

cto

r H

an

d F

HL

-1.

Infe

ct.

Im

mu

n. 70

, 5

18

5-5

19

2 (

20

02

).

85

. M

eri,

T. e

t a

l. T

he

hyp

ha

l a

nd

ye

ast

form

s o

f C

an

did

a a

lbic

an

s b

ind

th

e c

om

ple

me

nt

reg

ula

tor

C4

b-b

ind

ing

pro

tein

. In

fect.

Im

mu

n.

72

, 6

63

3-6

64

1 (

20

04

).

86

. P

olte

rma

nn

, S

. e

t a

l. G

pm

1p

is a

fa

cto

r H

, F

HL

-1

an

d p

lasm

ino

ge

n-b

ind

ing

su

rfa

ce

pro

tein

of

Ca

nd

ida

alb

ica

ns. J. B

iol. C

he

m.

(20

07

).

©!2008!N

atu

re P

ub

lis

hin

g G

rou

p

complement evasion by human pathogens - lambris · surface way, the complement cascade also...

Documents